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Abstract
Estimating the causal effect of a binary intervention or action (referred to as a “treatment”)
on a continuous outcome is often an investigator’s primary goal. Randomized trials are ideal
for estimating causal effects because randomization eliminates selection bias in treatment
assignment. However, randomized trials are not always ethically or practically possible,
and observational data must be used to estimate the causal effect of treatment. Unbiased
estimation of causal effects with observational data requires adjustment for confounding
variables that are related to both the outcome and treatment assignment. Adjusting for
all measured covariates in a study protects against bias, but including covariates unrelated
to outcome may increase the variability of the estimated causal effect. Standard variable
selection techniques aim to maximize predictive ability of a model for the outcome and are
used to decrease variability of the estimated causal effect, but they ignore covariate associ-
ations with treatment and may not adjust for important confounders weakly associated to
outcome. We propose two approaches for estimating causal effects that simultaneously con-
sider models for both outcome and treatment assignment. The first approach is a variable
selection technique for identifying confounders and predictors of outcome using an adaptive
group lasso approach that simultaneously performs coefficient selection, regularization, and
estimation across the treatment and outcome models. In the second approach, two meth-
ods are proposed that simultaneously model outcome and treatment assignment using a
Bayesian formulation with spike and slab priors on each covariate coefficient; the Spike and
Slab Causal Estimator (SSCE) aims to achieve minimum bias of the causal effect estimator
while Bilevel SSCE (BSSCE) aims to minimize its mean squared error. We also propose
TEHTrees, a new method that combines matching and conditional inference trees to char-
acterize treatment effect heterogeneity. One of its main virtues is that, by employing formal
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Estimating the causal effect of a binary intervention or action (referred to as a “treatment”)
on a continuous outcome is often an investigator’s primary goal. Randomized trials are ideal
for estimating causal effects because randomization eliminates selection bias in treatment
assignment. However, randomized trials are not always ethically or practically possible,
and observational data must be used to estimate the causal effect of treatment. When
using observational data to estimate the casual effect of treatment, many methods require
either modeling the mean outcome conditional on the predictors and the treatment (e.g.,
regression modeling), or specifying a treatment allocation model (e.g., inverse probability
weighting (IPW) and propensity score matching), or both (e.g., doubly robust methods)
(Lunceford and Davidian, 2004). Methods that rely on only one such model require that the
model be specified correctly and adjust for at least all confounders – variables associated
with both treatment and outcome – for consistent estimation of the causal treatment effect.
Doubly robust methods, however, fit both an outcome and a treatment model and require
only one of them be specified correctly with all confounders for consistent treatment effect
estimation.
One approach is to include all available covariates in the specified model(s) to avoid
biased estimation. However, including many variables unrelated to outcome and treat-
ment could inflate the variance of the effect estimator. Hence, when there are a large
number of possible confounders, some type of variable selection is desirable to achieve unbi-
ased, efficient estimation. VanderWeele and Shpitser (2011) propose a confounder selection
criterion that controls for any covariate that is either a cause of treatment or outcome.
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Though efficiency may improve by including covariates related only to outcome, as shown
by Brookhart et al. (2006) for IPW estimators and de Luna, Waernbaum, and Richard-
son (2011) for non-parametric estimators of the average causal effect (ACE), including all
causes of treatment or outcome can still be sub-optimal as these studies also suggest effi-
ciency may decrease when controlling for variables that are related to the treatment but
not the outcome.
Variable selection methods (e.g., backward variable selection, lasso) based only on the
outcome (treatment, respectively) model are popular in practice, but because these methods
ignore the relationship between treatment (outcome) and covariates, these methods tend to
under-select confounding variables weakly related to the outcome (treatment) but strongly
associated with the treatment (outcome). Vansteelandt, Bekaert, and Claeskens (2012)
argue that omitting such variables in estimators of the ACE not only introduces bias but
also underestimates the uncertainty of the ACE and propose a method based on a focused
information criterion which aims at minimizing the mean squared error of the treatment
effect estimator.
There has been work to adapt traditional variable selection techniques, which focus on
covariates with the greatest predictive ability of treatment or outcome, to jointly select
covariates related to treatment and outcome. van der Laan and Gruber (2010) propose
a doubly robust semi-parametric method that solves an efficient influence curve equation
that is a function of the outcome and treatment models by utilizing numerous data adaptive
machine learning algorithms to select variables in a stepwise fashion for the propensity score.
Ertefaie, Asgharian, and Stephens (2015) proposed a two-step variable selection method
which selects variables using a penalized likelihood in the first step and then separately
estimates the causal treatment effect in the second step using a doubly robust regression
estimator. A limitation of this method, however, is that it may not select an important
confounder if its association with the outcome and treatment have opposite signs; this can
occur when the value of the coefficient in the outcome and treatment likelihoods are similar
in magnitude.
Bayesian model averaging (BMA) proposes taking a weighted average of the effect esti-
mates across models with different covariates included where the weights are determined by
the posterior model probability (Raftery, Madigan, & Hoeting, 1997). However, like tradi-
tional variable selection, standard BMA tends to prioritize models which include covariates
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strongly associated with outcome and may assign significant weight to models that include
only a subset of the necessary confounders, resulting in biased treatment effect estimation
(Crainiceanu, Dominici, & Parmigiani, 2008). Crainiceanu et al. (2008) introduce a two-
stage BMA method that forces strong predictors of treatment that are identified in a first
stage to be included in the outcome model in a second stage, and then strong predictors of
outcome that are not identified in stage one are identified in stage two. Wang, Parmigiani,
& Dominici (2012) propose Bayesian Adjustment for Confounding (BAC), a Bayesian model
averaging method on the outcome model with an informative prior obtained separately from
the treatment model (see Zigler & Dominici (2014) for related Bayesian methods that select
variables for propensity score estimation). BAC contains a prior dependence parameter,
ω, ranging from 1 to ∞ that links the treatment model to the outcome model. If ω = ∞,
all covariates with associations in the treatment model are forced into the outcome model,
whereas ω = 1 treats the two models independently and is equivalent to standard BMA on
the outcome model.
Two approaches have been predominantly used to select ω: (1) setting ω equal to ∞ as
the default and (2) selecting ω data-adaptively to minimize mean squared error (MSE) or
other criterion. Each approach is problematic. Setting ω =∞ targets the set of covariates
associated with treatment or outcome. However, we observe that BAC with ω = ∞ can
have high inclusion probabilities for irrelevant covariates that are unrelated to outcome and
treatment, particularly in smaller sample sizes. This can lead to inefficient estimators in
moderate sample sizes compared to other variable selection approaches which target the
same set of covariates (i.e., all variables associated with treatment or outcome). Further-
more, for a given sample size, selecting all covariates related to treatment and outcome may
not be the set which leads to the most efficient estimator of the average causal effect.
However, developing a data-adaptive approach to select ω to minimize MSE has proved
challenging. Lefebvre, Atherton, & Talbot (2014) proposed using cross validation or the
bootstrap to choose ω with the aim of minimizing MSE of the treatment effect estimator, but
they found that the performance of these procedures was sensitive to the underlying data
generating mechanism and suggested that alternative approaches should be investigated.
Even if cross validation or the bootstrap could be reliably used to choose ω, such methods
can be computationally intensive with large datasets. Further, BAC requires calculating the
Bayesian Information Criterion at each posterior draw, which cannot be calculated when
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the number of potential confounders in the model exceeds the sample size.
In Chapter 2, we propose GLiDeR (Group Lasso and Doubly Robust Estimation), a
treatment effect estimator which uses a modified adaptive group lasso approach (Yuan
and Lin, 2006) to perform simultaneous coefficient regularization and estimation for the
treatment and outcome models. Our method is more efficient than standard (doubly robust)
backward selection methods and is competitive with the two-stage BMA estimator proposed
by Cefalu et al. (2017). However, unlike the two-stage BMA estimator, our proposed method
is computationally feasible with a very large number of covariates including cases where the
number of covariates is larger than the sample size.
Chapter 3, we propose the Spike and Slab Causal Estimator (SSCE) and Bilevel SSCE
(BSSCE), novel Bayesian methods that simultaneously consider models for outcome and
treatment and use spike and slab priors on the covariate coefficients to encourage variable
selection based on associations in both the outcome and treatment models. SSCE aims to
minimize treatment effect bias by controlling only for covariates that are related to outcome
or treatment (and removing irrelevant ones), while BSSCE adjusts for the subset of the
covariates which minimize MSE of the treatment effect estimator. The proposed methods,
which are adapted from the formulation of the Bayesian group lasso with spike and slab
priors (Xu & Ghosh, 2015), are implemented using fast Gibbs samplers that perform well
with a large number of covariates, even when the number of covariates is greater than the
sample size.
Chapters 2 and 3 concern variable selection for the estimation of the average causal
effect. However, many policy and medical decisions are informed by heterogeneous treat-
ment effects that are found in the results of randomized studies. For example, BiDil is the
first drug to be FDA-approved for a single racial group because study results suggest it
is beneficial for African-Americans with congestive heart failure. However, if BiDil is not
truly beneficial for African-Americans with congestive heart failure (i.e., if a Type I error
was made), then production and marketing of the drug would prove to be very wasteful and
the potential side effects of BiDil would likely cause harm with no benefit for patients who
have received the drug.
Traditional approaches to characterizing treatment effect heterogeneity have centered
around regression modeling with interaction terms between the treatment/intervention indi-
cator and covariates. If treatment is randomized, the magnitude and statistical significance
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of the interaction term can be used to assess the degree of treatment effect heterogeneity.
However, when there are multiple interactions, regression models can quickly become diffi-
cult to interpret. Also, conclusions about the presence of interaction depend on the way in
which interaction terms are specified, so that important subgroups may not be identified.
Lastly, considering multiple interactions can inflate Type I error, but it is common not to
adjust the significance level for multiple testing, which leads to anti-conservative inference
(Green and Kern, 2012).
Recently, there has been increasing interest in developing techniques to estimate het-
erogeneous treatment effects using more flexible models that can “automatically” detect
subgroups of interest. Athey and Imbens (2016) developed Causal Tree, which uses a sin-
gle regression tree to recursively partition the data into homogeneous subgroups that have
similar treatment effects and a similar subset of covariate values. Wager and Athey (2017)
extend Causal Tree to Causal Forests, which averages treatment effect estimates over many
Causal Trees. Green and Kern (2012) propose another method that uses multiple regres-
sion trees, called Bayesian Adaptive Regression Trees (BART), which automatically detects
nonlinear relationships and interactions to describe treatment effect heterogeneity. While
many of these approaches provide flexible subgroup identification, they typically do not
address the issue of inflation of Type I error.
In Chapter 4, we propose a novel method, called Treatment Effect Heterogeneity Trees
(TEHTrees), for characterizing treatment effect heterogeneity. TEHTrees combines match-
ing with conditional inference trees (Hothorn and others, 2012). One of its main virtues is
that, by employing formal testing procedures in constructing the tree, TEHTrees preserves
Type I error. In simulation studies comparing TEHTrees and Causal Tree, the Type I error
rate is less than the desired 0.05 level in all considered scenarios using TEHTrees, but is
greater than 0.15 in all scenarios using Causal Tree (and far greater in some cases). Though
the power (defined as the probability of splitting on the variable with true heterogeneous
treatment effects) is slightly larger using Causal Tree compared to TEHTrees in our simula-
tions with continuous covariates, the power with binary covariates is actually greater using
TEHTrees compared to that of Causal Tree.
Chapter 2
Covariate selection with group
lasso and doubly robust estimation
of causal effects
2.1 Introduction
Estimating the causal effect of a binary intervention or action (referred to as a “treatment”)
on a continuous outcome is often an investigator’s primary goal. Randomized trials are ideal
for estimating causal effects because randomization eliminates selection bias in treatment
assignment. However, randomized trials are not always ethically or practically possible,
and observational data must be used to estimate the causal effect of treatment. When
using observational data to estimate the casual effect of treatment, many methods require
either modeling the mean outcome conditional on the predictors and the treatment (e.g.,
regression modeling), or specifying a treatment allocation model (e.g., inverse probability
weighting (IPW) and propensity score matching), or both (e.g., doubly robust methods)
(Lunceford and Davidian, 2004). Methods that rely on only one such model require that the
model be specified correctly and adjust for at least all confounders – variables associated
with both treatment and outcome – for consistent estimation of the causal treatment effect.
Doubly robust methods, however, fit both an outcome and a treatment model and require




One approach is to include all available covariates in the specified model(s) to avoid
biased estimation. However, including many variables unrelated to outcome and treat-
ment could inflate the variance of the effect estimator. Hence, when there are a large
number of possible confounders, some type of variable selection is desirable to achieve unbi-
ased, efficient estimation. VanderWeele and Shpitser (2011) propose a confounder selection
criterion that controls for any covariate that is either a cause of treatment or outcome.
Though efficiency may improve by including covariates related only to outcome, as shown
by Brookhart et al. (2006) for IPW estimators and de Luna, Waernbaum, and Richard-
son (2011) for non-parametric estimators of the average causal effect (ACE), including all
causes of treatment or outcome can still be sub-optimal as these studies also suggest effi-
ciency may decrease when controlling for variables that are related to the treatment but
not the outcome. Variable selection methods (e.g., backward variable selection, lasso) based
only on the outcome (treatment, respectively) model are popular in practice, but because
these methods ignore the relationship between treatment (outcome) and covariates, these
methods tend to under-select confounding variables weakly related to the outcome (treat-
ment) but strongly associated with the treatment (outcome). Vansteelandt, Bekaert, and
Claeskens (2012) argue that omitting such variables in estimators of the ACE not only
introduces bias but also underestimates the uncertainty of the ACE and propose a method
based on a focused information criterion which aims at minimizing the mean squared error
of the treatment effect estimator.
There has been work to adapt traditional variable selection techniques, which focus on
covariates with the greatest predictive ability of treatment or outcome, to jointly select
covariates related to treatment and outcome. van der Laan and Gruber (2010) propose a
doubly robust semi-parametric method that solves an efficient influence curve equation that
is a function of the outcome and treatment models by utilizing numerous data adaptive ma-
chine learning algorithms to select variables in a stepwise fashion for the propensity score.
Ertefaie et al. (2015) proposed a two-step variable selection method which selects variables
using a penalized likelihood in the first step and then separately estimates the causal treat-
ment effect in the second step using a doubly robust regression estimator. A limitation of
this method, however, is that it may not select an important confounder if its association
with the outcome and treatment have opposite signs; this can occur when the value of the
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coefficient in the outcome and treatment likelihoods are similar in magnitude. Wang, Parmi-
giani, and Dominici (2012) propose Bayesian adjustment for confounding (BAC), a method
linking the models for treatment and outcome with a dependence parameter. Cefalu et al.
(2017) take a similar approach to BAC by developing a two-stage Bayesian model averaged
(BMA) doubly robust method that introduces a prior dependence between a covariates’
inclusion in the propensity score and the outcome model that is designed to identify the
set of potential confounders based on their association with both treatment and outcome
by forcing variables included in the propensity score to be a subset of those included in
the outcome model. Despite improved efficiency over standard methods, these approaches
must estimate a posterior distribution on some model class, which is typically done using
measures (e.g., BIC) that cannot handle situations when the number of covariates is larger
than the sample size. Even when the number of predictors is less than the sample size,
these methods can be computationally intensive when the number of predictors is large as
they must explore all possible treatment and outcome model spaces; with even a modest
number of covariates, say 20, over 2 million (221) models must be considered. Moreover,
since treatment effect estimates are weighted linear combinations across many models, there
is no feature selection and interpretation of covariate effects is difficult.
In this chapter, we propose GLiDeR (Group Lasso and Doubly Robust Estimation),
a treatment effect estimator which uses a modified adaptive group lasso approach (Yuan
and Lin, 2006) to perform simultaneous coefficient regularization and estimation for the
treatment and outcome models. Our method is more efficient than standard (doubly robust)
backward selection methods and is competitive with the two-stage BMA estimator proposed
by Cefalu et al. (2017). However, unlike the two-stage BMA estimator, our proposed method
is computationally feasible with a very large number of covariates including cases where the
number of covariates is larger than the sample size.
We set up the problem and introduce the group lasso in Chapter 2.2. In Chapter
2.3, we formulate GLiDeR and summarize the estimation technique. Chapter 2.4 provides
theoretical justification and asymptotic results for GLiDeR. In Chapter 2.5 we present
simulation scenarios demonstrating the finite-sample behavior of GLiDeR, and Chapter
2.6 provides an application to an observational registry of lung transplant recipients. We
conclude in Chapter 2.7.
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2.2 Preliminaries
2.2.1 Doubly robust estimation of treatment effects
The causal effect of binary treatment A on continuous outcome Y is of interest. Letting
Y (a) denote the possibly counterfactual outcome for a randomly selected person if assigned
treatment A = a, the ACE is ∆ := E[Y (1) − Y (0)]. When A is randomized, the vector of
potential outcomes {Y (0), Y (1)} is independent of A. Given data (Yi, Ai) on independent








is a consistent estimator of ∆.
In an observational study, {Y (0), Y (1)} may depend on A and ∆̂ran may then be in-
consistent for ∆. However, it may be reasonable to assume that treatment assignment
is ignorable and has positive probability (positivity) given observed covariates, i.e., that
there exist covariates X = {X1, . . . , Xm} such that A ⊥ Y (a)|X and P (A = a|X) > 0,
for a = {0, 1}, in which case ∆ is consistent. We can then postulate a regression model
µ(A,X;α) for E(Y |A,X). If µ(A,X;α0) = E(Y |A,X) for some α0 (i.e., the outcome





i=1[µ(1,Xi; α̂)−µ(0,Xi; α̂)] is consistent for ∆ (Lunceford and Davidian, 2004).
If µ(A,X;α) 6= E(Y |A,X), then ∆̂reg may be inconsistent for ∆.
Let π(X; γ) be a postulated regression model for the conditional probability of treat-
ment, P (A = 1|X). If π(X; γ0) = P (A = 1|X) for some γ0 (i.e., the treatment model is
correctly specified), then a consistent estimator of ∆ is the inverse probability weighted










, where γ̂ is any consistent estima-
tor of γ0 (Lunceford and Davidian, 2004). If π(X; γ) 6= P (A = 1|X), then ∆̂IPW may be
an inconsistent estimator for ∆.
To address the problem of model misspecification, various authors have proposed doubly
robust estimators, which require specification of both an outcome and propensity score
model but require only one of them to be correctly specified to yield a consistent estimator






















The preceding has assumed that the observed covariates X are exactly those required
to achieve ignorability, i.e., X is precisely the set of confounders of the treatment-outcome
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relationship. However, in practice, we may have access to a large set of covariates V ⊃ X
which are candidates for inclusion in the outcome and treatment models. While the esti-
mators mentioned remain consistent if covariates from V \X are added to the propensity
and outcome models (in addition to X), in Chapter 2.4.1, we show that including covariates
related only to the outcome can decrease the variance – while adding covariates associated
with only the treatment can increase the variance – of the doubly robust estimator. In
Chapter 2.3, we introduce GLiDeR, a procedure for performing simultaneous variable se-
lection in treatment and outcome models that targets confounders and predictors of only
outcome.
2.2.2 The Group Lasso
Our approach to simultaneous variable selection in the outcome and treatment models uses
a modified version of the group lasso (Yuan and Lin, 2006) – a regularization method that
acts like the lasso (Tibshirani, 1996) on grouped covariates by forcing all coefficients of each
group of variables to be either all zero or all nonzero. We briefly introduce the group lasso
technique for a general regression model before describing our particular modification of it
in the next subchapter.
Let M be the q × 1 vector of covariates corresponding to a regression model for some
response variable R, and let ξ be the vector of associated regression coefficients. In the group
lasso, we assume that M is partitioned into K groups {M1, . . . ,MK}; the corresponding
blocks of ξ are denoted by ξ(1), . . . , ξ(K). For a general loss function Φ(R,M; ξ), the group





i=1 Φ(Ri,Mi; ξ) + λ
∑K
k=1wk‖ξ(k)‖2, where
λ > 0 is the penalty parameter and wk ≥ 0 is the penalty weight for group k. A common
choice for each group weight wk is
√
ck, where ck is the cardinality of group k (i.e., the
number of elements in Mk). If we do not want to penalize a specific group, for example an
intercept, we let the corresponding wk equal 0. There is no closed form solution to ξ̂GL(λ),
but several algorithms exist, including the groupwise majorization descent (GMD) algorithm




Let Vi = {V1i, . . . , Vpi} denote subject i’s vector of measured covariates, with p possibly
large in relation to the sample size n; for the remainder of the chapter, we suppress i in our
notation except where necessary. We assume as in Chapter 2.2.1 ignorability and positivity
of treatment assignment given V. Let outcome and propensity models for E(Y |A,V)
and P (A = 1|V) be defined by f [µ(A,V;α)] = α1V1 + · · · + αpVp + αp+1 + αp+2A, and
g[π(V; γ)] = γ1V1 + . . . γpVp + γp+1, and let Φout(Y,A,V;α) and Φtrt(A,V; γ) denote the
outcome and treatment loss functions used to fit these models. In many doubly robust
treatment effect estimation problems, f is taken to be the identity function and g is the logit
function, so that the outcome and treatment models represent linear and logistic regression.
In this case, Φout is the squared error loss and Φtrt is proportional to the binomial negative
log-likelihood.
Anticipating the group lasso approach in the next subchapter, we will let β = (α, γ) and
define p + 3 groups of this vector: β1 = (α1, γ1), . . . , βp = (αp, γp), βp+1 = αp+1, βp+2 =
γp+1, and βp+3 = αp+2. Note that, for k = 1, . . . , p, βk is a group of coefficients corre-
sponding to the covariate Vk in the outcome and treatment model, respectively. Our setup
differs from the typical one for group lasso, as our groupings correspond to the same covari-
ate appearing in two different regression models, as opposed to sets of related but distinct
covariates within the same regression model. Covariate transformations may be included
by adding the necessary elements to V and grouping the coefficients of the transformed
covariates with those of the untransformed versions. In this manuscript, we do not consider
interactions between covariates; while including interactions poses no technical challenges,
it is not clear to which group the corresponding columns in the design matrix for the inter-
action should belong.
2.3.2 Simultaneous variable selection for the treatment and outcome mod-
els
To perform simultaneous variable selection between the treatment and outcome models, we
propose to solve a group lasso-like problem with the following characteristics:
(1) The loss function is taken to be the sum of the loss functions for the treatment and
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outcome models,
Φsum(Y,A,V;β) = Φout(Y,A,V;α) + Φtrt(A,V; γ). (2.2)
(2) We use the penalty term











so each summand corresponds to the coefficients associated with a single covariate; λ > 0
is the penalty parameter and Wk is a weight term with Wk = 0 for k > p, that is we do
not penalize the intercepts in the treatment and outcome models and the main effect of
treatment in the outcome model. We discuss the choice of Wk in Chapter 2.3.3. Unlike the
usual group lasso setup, where related covariates in the same model are jointly penalized,
GLiDeR groups together the coefficients corresponding to the same covariate across the
treatment and outcome models. This strategy forces covariates to enter and leave the
models simultaneously.











where Ystd = Y/sd(Y ) is used instead of Y in Equation (2.3) so the scale of Φout(Y,V;α)
(and Φsum(Y,A,V;β), by definition) does not depend on the measurement unit of continu-
ous Y ; and, therefore, estimation of β is not affected by the scale of Y . We also assume the
covariates used in (2.3) are standardized so that the penalty is invariant to scale. Given a
solution β̂(λ) of (2.3), we can plug β̂(λ) = {α̂(λ), γ̂(λ)} into µ{A,V; α̂(λ)} and π{V; γ̂(λ)}
to obtain an estimate of ∆ at each λ, denoted ∆̂DR(λ), using Equation (2.1). As with the
usual (group) lasso, the degree of variable selection is controlled by λ. We discuss choosing
λ in Chapter 2.3.4.
2.3.3 Choosing Wk
Because our goal is to minimize the mean squared error of the treatment effect estimator
and, therefore, encourage selection of covariates which are associated with the outcome
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(which includes confounders) and discourage selection of covariates which are related only




where the numerator corresponds to the cardinality of group k (the default group penalty
weight under the general group lasso formulation) and vk 6= 0 is an estimate of the regression
coefficient in the outcome model for covariate k from a “full” model. When p+ 2 ≤ n, one
can set vk to be the ordinary least squares estimate for covariate k as obtained when fitting
the full outcome model. In cases where p+ 2 > n, one choice is the least squares coefficient
estimate of covariate k with the ridge penalty. With transformations in the outcome or
treatment model, Wk can be defined by setting the numerator equal to the square root of
the total number of predictors in the outcome and treatment models that correspond to
covariate k, and vk equal to the l2 norm of the corresponding estimated coefficients. When
the weights vary based on the strength of the association between the covariate and outcome,
we refer to GLiDeR as “adaptive.” Ertefaie et al. (2015) also propose an adaptive weight so
that the magnitude of the penalty on each coefficient is proportional to its contribution to
the outcome model but is different than the adaptive weight proposed here as it depends on
the least squares (or ridge) estimates of the coefficients in both the outcome and treatment
models. Like the general group lasso, if we do not want to penalize a specific group, which
is often the case for intercepts or the main effect of treatment in the outcome model, we set
the corresponding group weights Wk to zero. This proposed group weight strongly penalizes
covariates that are not associated with the outcome (i.e., when |vk| is small) even if they are
strongly associated with the treatment. Hence, the adaptive approach used in GLiDeR is
aimed to select covariates associated with only the outcome or confounders that are related
to both treatment and outcome (i.e., covariates related to the treatment should be selected
only if they are also associated with the outcome).
2.3.4 Choosing λ
Equation (2.3) defines the solution β̂(λ) as a function of λ. We propose to choose λ by
applying cross-validation to the outcome model, since doing so further encourages the (de-
sirable) selection of predictors associated with the outcome. Generalized cross-validation
(GCV) or k-fold cross-validation (kCV) is typically used to select the tuning parameter λ in
lasso-like problems. Since we consider both outcome and treatment model loss functions in
Equation (2.3) but wish to apply GCV to only the outcome model, the usual GCV statistic
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requires a modification (kCV is straightforward). For the general group lasso, the GCV
statistic at a particular value λ is RSS












(dj − 1), where ξ̂aGLj and ξ̃aGLj are the adaptive
group lasso and least squares estimators of the jth group of coefficients, respectively, for
groups j = 1, . . . ,K with group sizes dj . For GLiDeR, since we want a model selection pro-
cedure for the outcome model only, we take the residual sum of squares from the outcome
model to use in the numerator and use only the parts of β̂(λ) corresponding to coefficients
from the outcome model (denoted α̂(λ)) in the denominator, yielding the following modified
GCV statistic (noting we have p “groups” of size 2 and 2 terms – the intercept αp+1 and

















Then λ∗ = min
λ
GCV (λ) is the “optimal” λ. GCV is computationally advantageous since
it only needs to be computed from the data once (as opposed to kCV, which needs to
be computed an additional k times), and also demonstrates slightly better performance
than kCV in the simulation scenarios considered in Chapter 2.5 (see Table 2.7 for results
comparing GCV and kCV). We thus recommend using the GCV statistic in Equation (2.4)
to select λ. Our final estimate of ∆ is then ∆̂DR(λ
∗) in Equation (2.1).
2.3.5 Implementation
To summarize, we now list the steps involved in implementing the GLiDeR procedure.
Step 1 - Define covariate groups: Group outcome and treatment model predictors
(assumed to be standardized) as described in Chapter 2.3.1. For each group k, compute
group weights Wk as described in Chapter 2.3.3. For groups k that represent intercepts in
either model or the treatment main-effect term in the outcome model, let the corresponding
group weight Wk be zero. Scale Y by its marginal standard deviation, as discussed in
Chapter 2.3.2.
Step 2 - Apply the modified group lasso. Define a sequence of λ values λ1, . . . , λL,
such that λ1 > λ2 > · · · > λL ≥ 0 with initial value λ1 defined to be the smallest value λ
such that all predictors have zero coefficients, except the terms with group weights (Wk)
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equal to zero. For l = 1, . . . , L, apply the GMD algorithm described in Yang and Zou
(2015). Chapter 2.8.1 gives details of adapting this algorithm for this application.
Step 3 - Select the final model and estimate the doubly robust treatment effect.




β̂(λ∗) = (α̂, γ̂) into µ(A,V; α̂) and π(V; γ̂) and obtain an estimate of ∆ using Equation
(2.1).
2.4 Asymptotic results
2.4.1 Efficient variable sets for doubly robust estimators
We begin by showing that including covariates related only to the treatment may increase –
while including those related only to the outcome may decrease – the asymptotic variance of
the doubly robust estimator, thereby justifying the covariate sets GLiDeR seeks to identify.
We consider doubly robust estimators in the class of (2.1) and focus attention on esti-
mating µ1 = E {Y (1)}; ideas are similar for estimating E {Y (0)} and, therefore, the ACE,

























= 0. If the models are correctly specified, then α∗ and γ∗ are the
“true” values of the parameters, and if incorrectly specified, then these are the “least false”
parameters. To investigate the effect of including certain types of covariates in ∆̂DR,µ1 , we
will consider the case that γ = γ∗ and α = α∗ are known, so that π(V; γ∗) and µ(A,V;α∗)
are known functions of V. When one or both models are correctly specified, we can then
show the asymptotic variance of
√








which follows from the iterated conditional variance formula. Now consider a new covariate,
Z1, and assume that γ
∗
Z1
6= 0 and α∗Z1 = 0, where γ
∗
Z1
and α∗Z1 are the true/least false re-
gression coefficients for Z1 in the treatment and outcome models, respectively. That is, Z1
is conditionally (given V) related to treatment, but conditionally unrelated to the outcome.
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Then the asymptotic variance of
√
n∆̂DR,µ1 with V and Z1 is
ΣDR(V, Z1) = V ar{Y (1)}+E
[
1− π(V, Z1; γ∗, γ∗z1)
π(V, Z1; γ∗, γ∗z1)
E
[






















(Y (1)− µ(1,V;α∗))2|V, Z1
]]
.




ΣDR(V). If Z1 is






σ2 is the variance of Z1. Then as Z1 is associated with treatment, γ
∗






> 1 so that ΣDR(V, Z1) > ΣDR(V), and ΣDR(V, Z1) gets larger as |γ∗z1 | in-
creases. The same derivation holds for covariate Z∗1 = Z1−E(Z1|V) (i.e., Z∗1 is independent
of V and α∗Z∗1
= 0 ) when Z1 and V are multivariate normal and dependent.
If we instead consider an irrelevant covariate, Z2, which follows the same assumptions





then a similar argument can be made to show that ΣDR(V, Z2) = ΣDR(V). Lastly, consider
covariate Z3, which is assumed to be conditionally related to outcome but conditionally
unrelated to treatment. Then the asymptotic variance of
√
n∆̂DR,µ1 with V and Z3 is










which follows assuming γ∗z3 = 0 (the truth). When the outcome model is correctly specified,
E
[








which implies ΣDR(V, Z3) < ΣDR(V) when the regression error does not depend on co-
variates (i.e., homoscedastic); when the outcome model is misspecified, ΣDR(V, Z3) <
ΣDR(V) under homoscedasticity if prediction of Y (1) via µ(1,V, Z3;α
∗, α∗z3) is improved
over µ(1,V;α∗).
In practice, α and γ are not known and must be estimated. M-estimation techniques
can be used to derive the asymptotic variance of the doubly robust estimator when α and
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γ are estimated, but such derivations do not provide any obvious expressions that reveal
the effect on the asymptotic variance of the doubly robust estimator after adding Z1, Z2,
or Z3 when one of the models is misspecified; when both models are correctly specified, the
asymptotic variance is the same regardless of whether α and γ are known or estimated.
2.4.2 Targeted covariate sets and double robustness of GLiDeR
We now show GLiDeR can asymptotically recover the set of confounders and covariates
related only to outcome, while excluding irrelevant variables and covariates related only to
treatment. Specifically, GLiDeR selects a covariate Vj provided α
∗
Vj
6= 0. The key theorem
is described here; the proof, which uses concentration inequalities from Blazère, Loubes,
and Gamboa (2014), appears in Chapter 2.8.2.
Assume no transformations or interactions between covariates (i.e., all groups are of size
2) so that Wk =
√
2
|vk| as in Chapter 2.3.3. Assume further that there are no confounders such
that α∗Vj = 0 if the outcome model is misspecified (i.e., the covariate has no linear association
with the outcome, which rules out symmetric quadratic or periodic relationships). Then
the group weight (Wk) tends to infinity for any covariate that is unrelated to the outcome,
which allows covariates that are irrelevant or related only to treatment to be asymptotically
excluded from GLiDeR. We can then prove the following theorem:
Theorem 1. Assume the number of covariates p and sample size n are such that log(2p)n ≤







g 6= 0). Then, for sufficiently large λn and with high probability, we have
p∑
g=1





















where 0 < k < 1 and cn > 0 are defined in Chapter 2.8.2.
β∗ = (α∗, γ∗)T denotes the true/least false coefficient parameters of the outcome and
treatment models. The Group Stabil condition – a lower bound on the eigenvalues of the
covariance matrix – and cn are discussed in greater detail in Chapter 2.8.2.
The implication of Theorem 1 is that if ζ∗ = O(1), i.e., the number of groups containing
non-zero coefficients does not increase with n, then for suitable λn (described in Chapter
2.8.2)
∑p









p→ γ∗g for all g such that α∗g 6= 0 provided the rate of increase in the number of
covariates is o(en). Consequently, under the assumptions given above and in Theorem 1,
GLiDeR asymptotically recovers all covariates associated with the outcome, which includes
the confounders, even when the outcome model is misspecified, and combined with the
estimator in (1), yields a consistent estimator of ∆ when either the outcome or treatment
model is correctly specified. However, we note that GLiDeR is not doubly robust in the




We investigate the finite sample behavior of GLiDeR relative to four alternative variable
selection approaches to fit models used in treatment effect estimators: (1) the “saturated”
method which uses all covariates in fitting the outcome and treatment models to compute
∆̂DR; (2) backward selection on the outcome model (p-stay < 0.05) to select the covariates
which are used in fitting the outcome and treatment model to compute ∆̂DR, (3) two-
stage model averaged double robust (MADR) estimator proposed by Cefalu et al. (2017),
and (4) adaptive lasso (Zou, 2006) to select covariates and estimate the treatment effect
using only the outcome model (10-fold cross-validation to select tuning parameter). Note
that the first three methods are doubly robust while the adaptive lasso does not consider
a model for the treatment. Numerous simulation scenarios are considered to evaluate the
effects of varying levels of confounding, model misspecification, covariate structure, number
of irrelevant variables (i.e., covariates unrelated to outcome and treatment), and sample
size. For each scenario, we generate potential confounders V = {V1, ..., Vp} marginally as
N(µv, σ
2
v), treatment A as Bernoulli[expit{f(V)}] for some function f(·), where expit(x) =
exp(x)
exp(x)+1 , and outcome Y as N{A+ g(V), σ
2
y} for some function g(·).
To vary levels of confounding and model misspecification, we consider the same nine
distinct combinations of f(V) and g(V) as in Cefalu et al. (2017) (we refer to these as
Scenarios 1–9) with both independent and correlated covariates, and one from Ertefaie et
al. (2015) (referred to as Scenario 10) with only independent covariates, which are described
in Table 2.1. For Scenarios 5–9 (which were used in a previous version of Cefalu et al. (2017))
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Table 2.1: Scenarios considered. Treatment A is generated as Bernoulli[expit{f(V)}], and
outcome Y is generated as N(A+ g(V), σ2y) where σ
2 = 1 for Scenarios 1–9 and σ2y = 4 for
Scenario 10.
Scenario f(V) (Treatment) g(V) (Outcome)
1 0.4V1 + 0.3V2 + 0.2V3 + 0.1V4 0
2 0.5V1 + 0.5V2 + 0.5V3 + 0.1V4 0.5V1 + V3 + 0.5V4
3 0.1V1 + 0.1V2 + V3 + V4 + V5 2V1 + 2V2
4 0.5V1 + 0.4V2 + 0.3V3 + 0.2V4 + 0.1V5 0.5V1 + V2 + 1.5V3 + 2V4 + 2.5V5












7 0.2V1 + 0.2V2 + 0.2V5 0.25V3 + (V1 + V2)
2 − (V 21 − V3)2+
(V 24 − 0.5V5)(V3 − 0.5V4)





ViVj 0.5V1 + 0.5V2 + 0.1V3
9 (X1 +X2 + 0.5X3)
2 0.5V1 + 0.5V3 + 0.5V4
10 0.2V1 − 2V2 + V5 − V6 + V7 − V8 2V1 + 0.2V2 + 5V3 + 5V4
f(V) or g(V) (but not both) is a polynomial function of the covariates, while all methods
assume f(V) and g(V) to be linear functions of the covariates, so that the outcome or
treatment model (but not both) is misspecified in these scenarios. We also varied the total
number of covariates available for Scenarios 1–9 by considering p = 5, 10, and 25 (we do
not consider MADR for p = 25 as this would require fitting over 6 million models for
each dataset) with a sample size of n = 500, and we varied the sample size by considering
n = 250 and n = 500 with 10 covariates. For Scenario 10 we consider p = 100, p = 500,
and p = 1000 with a sample size of n = 500 and only consider GLiDeR and the adaptive
lasso, and compare them to the saturated method with a ridge penalty for both models
due to the large number of covariates. Bootstrap 95% percentile confidence intervals of
the treatment effect estimate using GLiDeR are calculated for Scenarios 1–9 and Scenario
10 with p = 100 using 1,000 bootstrap samples. All results represent averages over 1,000
Monte Carlo datasets.
2.5.2 Results
Table 2.2 shows the ratio of mean squared error (MSE) of the average causal treatment
effect of GLiDeR, backward selection, MADR, and adaptive lasso (denominator) relative
to the saturated variable selection method (numerator) and Monte Carlo (MC) bias and
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Table 2.2: Ratio of MSE (saturated model MSE / alternative method MSE) and Monte
Carlo (MC) bias and standard errors for each scenario with sample size n = 500 over 1,000
MC datasets. Scenarios 1–9 have 10 covariates and Scenario 10 has varying covariate set
sizes (p). In the simulations with correlated covariates, ρ(Vi, Vj) = 0.6 for i 6= j ≤ 5 and
ρ(Vi, Vj) = 0 for i 6= j > 5.
GLiDeR Backward selection MADR Adaptive lasso
Scenario
MSE MC MC MSE MC MC MSE MC MC MSE MC MC
Ratio Bias SD Ratio Bias SD Ratio Bias SD Ratio Bias SD
Independent covariates
1 1.10 0.00 0.09 1.02 0.00 0.09 1.11 0.00 0.09 1.12 0.00 0.09
2 1.09 0.00 0.09 1.02 0.00 0.10 1.12 0.00 0.09 1.13 0.00 0.09
3 2.91 0.00 0.09 1.04 0.00 0.15 3.06 0.00 0.09 3.20 0.00 0.09
4 1.01 0.00 0.10 1.01 0.00 0.10 1.02 0.00 0.10 0.79 0.05 0.10
5 1.67 -0.04 0.63 1.05 -0.04 0.80 1.65 -0.03 0.64 1.64 -0.04 0.64
6 18.35 0.00 0.31 0.95 -0.03 1.36 18.53 0.00 0.31 16.30 0.00 0.33
7 1.14 -0.05 0.84 1.04 -0.06 0.88 1.12 -0.05 0.85 1.16 -0.05 0.83
8 1.26 0.01 0.12 1.04 0.01 0.13 1.25 0.02 0.12 1.35 0.01 0.11
9 1.05 0.00 0.11 1.04 0.00 0.11 1.06 0.00 0.11 1.06 0.00 0.11
Correlated covariates
1 1.16 0.00 0.09 1.01 0.00 0.10 1.20 0.00 0.09 1.20 0.00 0.09
2 1.09 0.00 0.10 1.02 0.00 0.10 1.09 0.00 0.10 1.14 0.02 0.10
3 5.55 0.00 0.13 0.94 -0.02 0.32 5.29 -0.01 0.14 7.49 0.02 0.11
4 1.05 0.01 0.11 1.04 0.01 0.11 1.08 0.01 0.11 0.25 0.20 0.11
5 3.30 0.39 1.99 1.02 0.05 3.64 2.68 0.45 2.20 2.14 0.99 2.15
6 305.39 -0.02 0.92 1.61 -0.10 12.69 74.41 0.02 1.86 199.97 0.05 1.14
7 1.27 0.06 0.86 1.09 0.05 0.93 1.15 0.07 0.91 1.96 0.05 0.69
8 1.28 0.01 0.15 1.12 0.01 0.16 1.29 0.02 0.15 1.29 0.02 0.15
9 1.05 0.00 0.11 1.06 0.00 0.11 1.06 0.00 0.11 1.06 0.00 0.11
Scenario 10
p = 100 1.60 0.00 0.26 * * * * * * 0.51 -0.42 0.20
p = 500 13.65 -0.06 0.32 * * * * * * 6.22 -0.42 0.20
p = 1000 13.76 -0.14 0.29 * * * * * * 7.43 -0.39 0.20
Bold indicates significant difference (5% significance level) between MSEs (testing equality) from the saturated
method (full model) vs. the alternative method using the paired t-test.
standard deviation for a sample size of 500 and 10 covariates (Scenarios 1-9). Additional
results for different sample sizes and number of covariates are given in Chapter 2.8.3. Note
that a larger value for the MSE ratio indicates better performance, with a MSE ratio greater
than one demonstrating improved treatment effect estimation over the saturated method.
Apart from a few exceptions, all MSE ratios are greater than one as including all covari-
ates available (saturated method) generally led to treatment effect estimates with higher
MC variance. Additionally, backward selection shows a smaller MSE ratio than MADR and
GLiDeR in all scenarios except one (Scenario 9 with correlated covariates, where the three
ratios are similar) as using backward selection on the outcome model to select covariates for
treatment effect estimation was generally more variable than performing variable selection
across both the outcome and treatment models (GLiDeR, MADR).
Comparing GLiDeR and MADR, when both models were specified correctly (Scenarios
1–4) or when only the treatment models were misspecified (Scenarios 8 and 9), GLiDeR
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and MADR performed similarly. However, in all scenarios where the outcome models were
misspecified (Scenarios 5–7) with correlated covariates, GLiDeR displayed a less variable
treatment effect estimator and significantly greater MSE ratio than MADR; the methods
performed similarly in these scenarios with independent data.
The adaptive lasso approach considered here uses only the outcome model for estimation
of the treatment effect and is, therefore, more efficient than doubly robust methods when
the outcome model is correctly specified. This approach outperformed all methods with
a correctly specified outcome model, except Scenarios 4 and 10 with p = 100, where it
displayed much greater MC bias and performed significantly worse (MSE ratio < 1) than all
methods. In these two scenarios, there is a confounder weakly associated with the outcome
but strongly related to treatment (V1 in Scenario 4 and V2 in Scenario 10). The adaptive
lasso tends to omit these variables as it considers only the associations in the outcome model
and ignores the relationships between treatment and covariates. Excluding these important
confounders in Scenarios 4 and 10 introduces a large bias and consequently larger MSE
compared to the other methods. GLiDeR, however, selects this important confounder in
nearly all datasets in these scenarios (see Table 2.8 for percentage of datasets each covariate
is selected by GLiDeR) and accordingly has much smaller bias than adaptive lasso using only
the outcome model. In Scenario 10 when the number of irrelevant covariates is increased
(p = 500 and p = 1000; n = 500), the bias of GLiDeR also increases as it becomes more
challenging to select X2, but the bias is much smaller than that of adaptive lasso and, even
with a larger variance, GLiDeR has an MSE ratio approximately twice that of the adaptive
lasso. Even with the large bias of the adaptive lasso, it is more efficient than using all
covariates with ridge penalty with p = 500 and p = 1000.
GLiDeR achieved coverage rates very close to the nominal 95% in all scenarios that were
considered for confidence interval coverage (see Table 2.9).
2.5.3 Computation time
GLiDeR is dramatically faster than MADR, making it feasible to apply in problems where
p is much larger. With p = 10 covariates and sample size n = 500, GLiDeR required
3 seconds while MADR required 10. However, the computation time of GLiDeR scales
linearly with the number of covariates p, while the computation time of MADR scales
exponentially as 2p. For instance, MADR would take over 1, 000 hours with 30 covariates
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(ignoring the time for storage and other necessary calculations), while GLiDeR solves the
same size problem in less than 20 seconds; in Scenario 10 with sample size n = 500 and
p = 100, p = 500, and p = 1000, GLiDeR took approximately 20 seconds, 3.5 minutes, and
11 minutes, respectively, to compute the ACE per dataset over a sequence of 100 λ. All
computations were performed using a pure R implementation, rather than a faster language
like C.
2.6 Application
Bilateral lung transplant (BLT) is generally associated with lower short-term survival, but
higher quality of life compared to single-lung transplant (SLT) for individuals with lung
disease (Aziz et al., 2010). Consequently, the effect of BLT (vs. SLT) on physiologic
measures associated with quality of life, such as forced expiratory volume in one second
(FEV1), is important for patients who must decide between the two treatment options.
Data on lung transplant recipients from May 2005 – September 2011 were obtained from
the United Network for Organ Sharing national registry. In this analyses, we focus on
patients aged 60 or older with obstructive lung disease (e.g., COPD). The dataset consists of
937 patients (52.7% receiving BLT) and 31 potential confounders, which are summarized in
Table 2.10. Missing covariate data were imputed using Multivariate Imputation by Chained
Equations (MICE) (Van Buuren and Groothuis-Oudshoorn, 2011). The outcome is FEV1%
one year after transplant, where FEV1% is defined as the percentage of the predicted value
of FEV1 given the person’s age, height, gender, and race. Patients who died were given
an FEV1 of 0, the worst possible score. We assume linear and logistic regression models
for the outcome and treatment (BLT vs. SLT), respectively. With 31 covariates, we would
have to fit 232 (over 4 billion) models to estimate the treatment effect using model averaged
methods, making GLiDeR an appealing option.
We estimated coefficient values for a sequence of 100 λ values ranging from 0 to the
smallest value of λ such that all coefficients are zero. We then selected the optimal λ
(denoted λ∗) using GCV on the outcome model as described in Chapter 2.3.4. For all
methods, 1,000 bootstrap samples were used to estimate standard errors and obtain 95%
percentile-based confidence intervals (CIs) of the treatment effect estimates. Figure 2.1
shows the estimated coefficients from the outcome and treatment models for a subset of
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Table 2.3: Variables selected and estimated coefficients (for standardized variables and
outcome) by GLiDeR and backward selection.
GLiDeR Backward selection
Covariate Outcome Coef Treatment Coef Outcome Coef Treatment Coef
Ischemic time -0.075 -1.018 -0.060 -1.154
Age of recipient 0.097 0.171 0.114 0.270
PO2 0.032 -0.014 0.060 -0.079
Oxygen amount required -0.052 -0.088 -0.060 -0.261
6 minute walk distance 0.019 -0.004 0.061 -0.044
Height of recipient -0.058 0.008 * *
Height of donor -0.015 0.005 *
Local or regional (vs. national) allocation 0.034 0.096 * *
Center volume 0.010 -0.013 * *
Sex of recipient * * 0.092 -0.034
*Covariate was not chosen by method
λ values that were considered. Table 2.10 displays the selected covariates and estimated
coefficients by GLiDeR and backward selection; nine covariates were selected by GLiDeR
and six covariates were chosen by backward selection for final estimation of the treatment
effect. Figure 2.2 displays a forest plot comparing point estimates and 95% CIs of the ACE
of BLT (vs. SLT) on FEV1% one year after transplant for GLiDeR, backward selection,
and the saturated method.
Using backward selection on the outcome model as described in Chapter 2.5.1, the ACE
is estimated to be 34.7 with a standard error of 3.4, both equivalent (to one decimal place)
to the estimates obtained using all covariates, but with a slightly smaller 95% CI: (27.4,
38.7) with backward selection compared to (26.1, 39.1) using all covariates. The standard
errors and CI length using these methods are much larger than those achieved with GLiDeR,
where the estimated coefficients at λ∗ are used in the standard doubly robust estimator in
Equation (2.1) and the ACE of BLT (vs. SLT) is estimated to be 36.0 (FEV1% after one
year) with a corresponding standard error of 1.6 and 95% CI of (32.6, 38.9).
These results are consistent with simulations, where GLiDeR generally shows greater
efficiency over these methods as the number of covariates is increased (see Tables 2.4 and
2.6). Even though the differences in estimated treatment effects between GLiDeR and other
approaches appear small, the difference in sample means of FEV1% among the treated
(BLT) and untreated (SLT) is 33.9, meaning the gap between the effect estimate from
GLiDeR and other methods which incorporate covariates is larger than that between those
other methods and the sample mean difference. In settings where incorporating covariates
makes a bigger difference to the treatment effect estimate, GLiDeR may offer a substantial
gain in efficiency.
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Figure 2.1: Coefficient estimates for the outcome (top) and treatment (bottom) models. A
white box indicates a coefficient is equal to zero, while a darker box indicates a coefficient
is larger in magnitude. Variables are ordered by the magnitude of their outcome model
coefficients at λ = 0 (unpenalized model) from largest to smallest.
Outcome Model


































































Figure 2.2: Forest plot of point estimates and corresponding Bootstrap percentile 95%
confidence intervals of the ACE of BLT (vs. SLT) on FEV1% one year after transplant for















Doubly robust estimation of the average causal treatment effect requires working models
for both the outcome and treatment given possible confounders. When the number of pos-
sible confounders is large it is natural to consider some form of variable selection for the
outcome and treatment models. GLiDeR uses an adaptive group lasso approach to perform
coefficient regularization and estimation across both treatment and outcome models simul-
taneously, unlike traditional methods that consider only one model and are thus more likely
to exclude important confounders with weak associations in the model under consideration.
GLiDeR has desirable theoretical properties, and in simulation experiments outperforms
doubly robust approaches which do not incorporate variable selection. It achieves simi-
lar efficiency with existing techniques which perform variable selection across both outcome
and treatment models, but has substantial computational advantages over these approaches
and allows for situations with p > n. Simulations suggest the largest gains in efficiency are
achieved when the outcome is misspecified, a frequent occurrence in practice.
GLiDeR targets inference for the average causal treatment effect, ∆. Even though
GLiDeR displays good performance in the simulation scenarios considered in this chapter,
we caution that, like other model selection procedures, its finite sample performance at
certain local alternatives can potentially be quite poor, reminiscent of Hodges’ estimator
(Leeb and Pötscher, 2008). While the validity of bootstrap intervals was not explored in
this chapter, percentile bootstrap confidence intervals for ∆ had good coverage; how to
adapt promising recent developments in post-selection inference to our setting is an area of
future research.
2.8 Supplementary Materials
2.8.1 Supplement A: Existence of Unique Solution
Here, we present conditions under which the simultaneous variable selection problem defined
by Equation (2.3) in Chapter 2.3.2 has a unique solution. An immediate corollary is that a
solution exists when Φsum is given by a sum of the squared error and logistic loss, i.e., when
defining linear and logistic regression models for the outcome and treatment, respectively.








Yang and Zou (2015) show that Equation (2.3) has a solution provided the loss function
Φsum satisfies a so-called quadratic majorization (QM) condition, i.e., if and only if the
following two assumptions hold:
(i) L(β|D) is a differentiable function of β, i.e., ∇L(β,D) exists everywhere.
(ii) There exists a p x p matrix H, which may only depend on D, such that for all β, β∗
L(β|D) ≤ L(β∗|D) + (β − β∗)T∇L(β∗|D) + 1
2
(β − β∗)TH(β − β∗)
We state and prove the following extension to their result which characterizes a class of
loss functions of the form of Equation (2.2) that satisfy the QM condition:
Lemma 1. Let Φsum(Y,A, f, g) = Φout(Y, f) + Φtrt(A, g), where Φout is the loss func-
tion used to link outcome Y with predictors Z1 = {Z11, . . . , Z1r} through a linear predictor
f = αTZ1, and Φtrt is the loss function used to link treatment A with predictors Z2 =
{Z21, . . . , Z2s} through a linear predictor g = γTZ2. Let Z = {Z11, . . . , Z1r, Z21, . . . , Z2s}.
Assume Φout is differentiable with respect to the coefficient parameters in f and write
Φ′out =
∂Φout(Y,f)
∂f , and similarly, assume Φtrt is differentiable with respect to the coefficient
parameters in g and write Φ′trt =
∂Φtrt(A,g)
∂g . Then:
(1). If Φ′out and Φ
′
trt are Lipschitz continuous with constants C1 and C2 such that
(i) |Φ′out(Y, f1)− Φ′out(Y, f2)| ≤ C1|f1 − f2| ∀Y, f1, f2,
and
(ii) |Φ′trt(A, g1)− Φ′trt(A, g2)| ≤ C2|g1 − g2| ∀A, g1, g2,










exist and there are constants C3 and C4
such that
(i) Φ′′1 ≤ C3 ∀Y, f,
and
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(ii) Φ′′2 ≤ C4 ∀A, g





(i) Φout satisfies condition (1)(i) with constant C1,





≥ CL ∀A, g (i.e., Φ′′2 is bounded),
or
(i) Φtrt satisfies condition (1)(ii) with constant C1,





≥ CL ∀Y, f (i.e., Φ′′1 is bounded),
then the QM condition holds for Φsum and H =
2(C1+C∗2 )
n Z
TZ, where C∗2 = max {|C2|, |CL|}.
Proof. Before proving Lemma 1, we first present a lemma (without observation weights)
from Yang and Zou (2015):











(1). If Φ′f is Lipschitz continuous with constant C such that
|Φ′f (y, f1)− Φ′f (y, f2)| ≤ C|f1 − f2| ∀y, f1, f2,
then the QM condition holds for Φ and H = 2Cn X
TX.
(2). If Φ′′f =
∂Φ2(y,f)
∂f2
exists and Φ′′f ≤ C2 ∀y, f ,
then the QM condition holds for Φ and H = C2n X
TX.
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Proving (1): We have
|Φ′out(Y, f1)− Φ′out(Y, f2)| ≤ C1|f1 − f2| ∀Y, f1, f2,
and
|Φ′trt(A, g1)− Φ′trt(A, g2)| ≤ C2|g1 − g2| ∀A, g1, g2
Then condition (1) in Lemma 2 is satisfied for the outcome and treatment loss functions
with constants C1 and C2, respectively. This implies
|Φ′sum(Y,A, f1, f1)− Φ′sum(Y,A, f2, f2)|
= |Φ′out(Y, f1) + Φ′trt(A, f1)− Φ′out(Y, f2)− Φ′trt(A, f2)|
≤ |Φ′out(Y, f1)− Φ′out(Y, f2)|+ |Φ′trt(A, f1)− Φ′trt(A, f2)|
≤ C1|f1 − f2|+ C2|f1 − f2| ∀Y,A, f1, f2.
To prove (2) in Lemma 1: We have constants C3 and C4 such that Φ
′′
out(Y, f) ≤ C3 and
Φ′′trt(A, g) ≤ C4 for all Y, f, g. Then
Φ′′sum(Y,A, f, g) = Φ
′′
out(Y, f) + Φ
′′
trt(A, g) ≤ C3 + C4.
Finally, to prove (3) in Lemma 1: Assume condition (1) in Lemma 2 is satisfied for, say
(WLOG), Φout with constant C1, and also assume Φtrt satisfies condition (2) in Lemma
2 with constant C2 such that Φ
′′
trt ≥ CL. Then since Φ′′trt is bounded, we know Φ′trt is
Lipschitz continuous with constant C∗2 (bounded derivative implies Lipschitz continuity).
The proof then concludes following the proof of (1) with constants C1 and C
∗
2 . 
To use linear and logistic regression to model the outcome and treatment, respectively,
and (naturally) letting Φout be the squared-error loss function and Φtrt be the loss function




4 , meaning the
QM condition holds for H = (5/4)n Z
TZ by Lemma 1 condition (2).
When the QM condition is met (i.e., when the conditions of Lemma 1 are satisfied), we
are able to solve for β in Equation (2.3) using the groupwise-majorization-descent (GMD)
algorithm (for details, see Yang and Zou (2015)), a computationally efficient and unified
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algorithm allowing for general design matrices.
2.8.2 Supplement B: Proof of Theorem 1
Here, we provide a proof of Theorem 2 in the main text, which is re-stated here:
Theorem 2. Assume the number of covariates p and sample size n are such that log(2p)n ≤







g 6= 0). Then, for sufficiently large λn and with high probability, we have
p∑
g=1

































We recall that λn is the penalty, β̂ is the group lasso estimator in our set-up, β
∗ is
the vector of true/least false coefficient parameters in the outcome and treatment models,
and β∗g is the sub-vector of β
∗ associated with group g (in our case, covariate g). We let
p∗ be the total number of columns in the design matrices of the outcome and treatment
models (i.e, p∗ is the length of β∗), which we denote by Zout and Ztrt, respectively. We
assume (Zout,i,Ztrt,i,Yi,Ai) are i.i.d. copies of (Zout,Ztrt,Y ,A) for i = 1, . . . , n, where Y |Zout
and A|Ztrt are modeled by distributions Fout and Ftrt both on R and from the exponential
family, respectively, and Zout,i and Ztrt,i are the ith rows of Zout and Ztrt, respectively. The
natural parameter space is denoted by Θ := Θout ∪Θtrt, where
Θout =
{












L and B apply to assumptions (H.1–3):
(H.1): the pair of variables (Zout, Ztrt) are almost surely bounded by a constant L,
i.e., there exists a constant L > 0 such that
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||(Zout, Ztrt)||∞ ≤ L a.s.
(H.2): for all x ∈ [−L,L]p∗ , β∗Tx ∈ Int(Θ)




dg||β∗g ||2 ≤ B
We consider Λ =
{
β ∈ Rp∗ : ∀x ∈ [−L,L]p∗ , βTx ∈ Θ
}
. We define dg to be the size of
group g, g ∈ {1, . . . , Gn}, and let dmin := min
g∈{1,...,Gn}
dg and dmax := max
g∈{1,...,Gn}
dg denote
the smallest and largest group sizes, respectively. Letting Φsum(β) = Φsum(Y,A,Z;β), the
empirical process (Pn − P)(Φsum(β)) can be written as:
(Pn − P)(Φsum(β)) = (Pn − P)[Φout(β) + Φtrt(β)]
= (Pn − P)[Φout,l(β)] + (Pn − P)[Φout,Ψ(β)]
+ (Pn − P)[Φtrt,l(β)] + (Pn − P)[Φtrt,Ψ(β)],
where Φout,l = −Y α′Zout, Φout,Ψ = Ψout(α′Zout), Φtrt,l = −Aγ′Ztrt, and Φtrt,Ψ = Ψtrt(γ′Ztrt);
Ψ′′out(x) and Ψ
′′
trt(x) in Theorem 2 denote the second derivatives of Ψout(x) and Ψtrt(x), re-
spectively. Φ.,l is used to denote the linear part of Φ and Φ.,Ψ is used to denote the part
which depends on the link function between the canonical parameter and the linear pre-
dictor. For example, if modeling the outcome with linear regression (i.e., using squared
error loss), then Φout,Ψ = α
′Zout, and if modeling the treatment with logistic regression,






















for all g ∈ {1, . . . , Gn}, where Zgout,i and Z
g
trt,i denote the elements on the ith rows and gth
























||βg − β∗g ||2 + εn







B + εn and εn =
1
n .
We can then adapt the following propositions of Blazère et al. (2014):
Proposition 1. Provided the penalty term λn is chosen suitably large enough,
P (A ∩ B) ≥ 1− 2(C + 2)
(2Gn)A
2/2
for any A >
√
2, where C is a universal constant.
(Proof at the end of this subchapter) In other words, for some suitable values of λn
and provided Gn →∞, the event A∩B happens with probability tending to one, implying
the events A and B each also have probability tending to one. Propositions 2 and 3 below
provide upper bounds for the linear and non-linear parts of the empirical process on the
events A and A∩ B, each occurring with high probability (by Proposition 1), respectively:
Proposition 2. On the event A,








||β̂g − β∗g ||2.
Proof. We have





















































The last line follows from the Cauchy-Schwarz inequality, and the proposition follows on
the event A. 


















Lemma 3 bounds the difference between the estimated and true coefficients and is proved
at the end of this subchapter. The next proposition provides an upper bound for (Pn −
P)(Φsum,ψ(β∗)− Φsum,ψ(β̂)) and directly results from Lemma 3 and definition of B.
Proposition 3. On the event A ∩ B,








||β̂g − β∗g ||2 + εn

Lemma 4. Assume assumptions (H.1-3) are fulfilled. For all k ∈ N∗, there exists constants
CoutL,B and C
trt
L,B (which both only depend on L and B) such that E(|Y |k) ≤ k!(CoutL,B)k and
E(|A|k) ≤ k!(CtrtL,B)k.
L applies to assumption (H.1) and is a uniform bound for the maximum magnitude
of the covariates, and B applies to assumption (H.3) and bounds the l2 norm of the true
(grouped) covariates. Lemma 4 provides moment bounds for outcome Y and treatment
A and follows from Lemma 3.2 in Blazère et al. (2014) when
√
dg in assumption (H.2) in





Theorem 2 requires that the Group Stabil Condition be satisfied. We state it here:
Definition 1. Let Σ = E[(Zout, Ztrt)(Zout, Ztrt)T ]. Define H∗ = {g : β∗g 6= 0}, the index set
of the groups for which the corresponding sub vectors of β∗ are non-zero. Let c0 and ε > 0





for any δ ∈ S(c0, ε), where S(c0, ε) is called the restricted set and is defined for c0 and ε > 0












||δg||2 + ε}. A Σ which satisfies the
Group Stabil Condition is said to be GS(c0, ε, k).
Definition 1 is similar to the Group Stabil Condition proposed in Blazère et al. (2014),
the only difference is that
√





in the restricted set, S(c0, ε). The Group Stabil Condition places a lower bound
on the eigenvalues of the variance matrix, with the lower bound depending on the number
of non-zero covariate groups. In other words, it restricts the degree of correlation between
covariates in the design matrix.
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We can now prove Theorem 2 presented in Chapter 2.4.2:
Proof of Theorem 2:
The proof uses arguments similar to those in Blazère et al. (2014). Using the definition of

























Hence we get (adding P(Φsum(β̂)− Φsum(β∗)) to both sides)




















||β̂g − β∗g ||2 to both sides of the


















If g /∈ H∗, where we recall from Definition 1 that H∗ = {g : β∗g 6= 0} (i.e., the index set of
the groups for which the corresponding sub vectors of β∗ are non-zero), then ||β̂g − β∗g ||2 +





























i.e., β̂ − β∗ ∈ S(3, εn2 ). The next proposition provides a lower bound for P(Φsum(β̂) −
Φsum(β
∗)).
Proposition 4. On the event A ∩ B we have
P(Φsum(β̂)− Φsum(β∗)) ≥ cnE
[
(β̂T (Zout, Ztrt)− β∗T (Zout, Ztrt))2
]


























= P(Φout(β̂)− Φout(β∗)) + P(Φtrt(β̂)− Φtrt(β∗))
= P(Φout(β̂)− Φout(β∗)) + P(Φtrt(β̂)− Φtrt(β∗)).
Recall β = (α, γ)T where α are the regression parameters in the outcome model and γ are
























where α̃TZout is an intermediate point between α̂
TZout and α
∗TZout given by a second order
Taylor expansion of ψout. Since ψ
′
out(α
∗TZout) = E(Y |Zout) we find



































∥∥α̂g − α∗g∥∥2 ‖Zgout‖2 + Gn∑
g=1
∥∥α∗g∥∥2 ‖Zgout‖2 ,
where the first inequality and second line follows from the triangle inequality, the third line
follows because α̃TZout is between α̂
T
nZout and α
∗TZout, and the fourth line follows from






















Moreover, α∗ and α̂ belong to Λout, which is a convex set, so we know α̃ ∈ Λout, and
therefore, α̃TZout ∈ Θout a.s. It follows that

















We can use a similar argument to show



















P(Φsum(β̂)− Φtrt(β∗)) ≥ (c1n + c2n)E
[
(α̂Zout − α∗Zout)2 + (γ̂Ztrt − γ∗Ztrt)2
]
≥ (c1n + c2n)E
[











||β̂g − β∗g ||2 + cnE
[(

















be the covariance matrix. We have
E
[(
β̂Tn (Zout, Ztrt)− β∗T (Zout, Ztrt)
)2]
= (β̂ − β∗)TΣ(β̂ − β∗).
Because condition GS(3, εn2 , k) is satisfied (by assumption) we have
cn(β̂ − β∗)TΣ(β̂ − β∗) ≥ cnk
∑
g∈H∗









































||β̂g − β∗g ||2 + cnk
∑
g∈H∗
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g∈H∗ ||β̂g − β∗g ||
2
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dg||β̂g − β∗g ||2 + cnk
∑
g∈H∗
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Finally we conclude the proof using Proposition 1.
Proof of Proposition 1:
Let A >
√
2. Recall that we have assumed Gn and n are such that
log (2Gn)
n ≤ 1. We deduce


















with A > 1. Then











where A ≥ 1. Then
P{B} ≥ 1− 2C(2Gn)−A
2/2
where we recall κn := 17B +
2









with K chosen such that





















then P(A ∩ B) ≥ 1− (2dmax + 2C)(2Gn)−A
2/2. 
Proof of Lemma 3
The proof of Lemma 3 is based on convexity of the loss function and of the penalty, as
in Blazère et al. (2014), where the main idea is similar to the one used by Bühlmann









and β̃ := tβ̂ + (1 − t)β∗. By convexity of Φsum and the L2 norm, in
addition to the fact that β̂ satisfies (2.7), we find















On the event A ∩ B we have (from Propositions 2 and 3)

















































































||β̂g − β∗g ||2 ≤M.






















































We will define random variables {W gij} with j = 1, 2 (more generally, j = 1, . . . , dg) and
















for i = 1, . . . , n. The random variables {Wij}i=1,...,n are independent, identically distributed























By Jensen’s inequality, we obtain
E|W gi1|










m ≤ 2m max
k=1,...,m
{E|AiZtrt,i|kE|AiZtrt,i|m−k}.






Therefore E|W gij |m ≤ m!(2LC∗L,B)m, where C∗L,B = max{CoutL,B, CtrtL,B}. Hence the conditions
are satisfied to apply Bernstein’s concentration inequality (Bennett, 1962) with K = 2LC∗L,B
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and σ2 = 8(LC∗L,B)























































Proof of Lemma 6:
Proof. The proof rests on the following Lemma:







{|(Pn − P)(Φsum,Ψ(β∗)− Φsum,Ψ(β))|} .




































||γg − γ∗g ||2 ≤ R).
Notice that if we change Xi by X
′


































1Xj ,Yj + 1X′j ,Y ′j
then we have
(Pn − P)(Φsum,Ψ(β∗)− Φsum,Ψ(β))− (P′n − P)(Φsum,Ψ(β∗)− Φsum,Ψ(β))
= (Pn − P)(Φout,Ψout(α∗)− Φout,Ψout(α))− (P′n − P)(Φout,Ψout(α∗)− Φout,Ψout(α))























|Ψ′(γ̃TZ ′trt,i)||γ∗TZ ′trt,i − γTZ ′trt,i|
where α̃Zout,i is an intermediate point between α
TZout,i and α
∗TZout,i (using a first order
Taylor expansion of the exponential function, as in the proof to Proposition 4). Then,










































































































































































































We can apply McDiarmid’s inequality (also called the bounded difference inequality) to ZR
and obtain








Therefore if λn ≥ ADMwLR
√
8 log 2Gn
n with A > 0 then
P(ZR,out − EZR,out ≥ λn) ≤ (2Gn)−A
2
. (2.14)
Now we have to bound the mean EZR. To do this, we need the Symmetrization theorem and
the contraction principle (see Appendix A of Blazère et al. (2014)), and then let ε1, . . . , εn
be a Rademacher sequence independent of Zout,1, . . . , Zout,n and Ztrt,1, . . . Ztrt,n and let






||βg − β∗g ||2 ≤ R}. Then by the Symmetrization theorem and


























where the last bound follows from Holder’s inequality. By applying the theorem below from




















Theorem. (Blazère et al., 2014) Let X1, . . . , Xn be independent random variables on χ and
f1, . . . , fn real-valued functions on χ which satisfies for all j = 1, . . . , p and all i = 1, . . . , p
and all i = 1, . . . , n









































for all R > 0. 






||βg − β∗g ||2 ≤M
 ,




































||βg − β∗g ||2 ≤ 2jεn

where jn := [log2 (nM)] + 1 is the smaller integer such that 2jnεn ≥M . We recall that
vn :=





||βg − β∗g ||2 + εn
and to simplify notation let
α(β, β∗) := (Pn − P)(Φsum,Ψ(β∗)− Φsum,Ψ(β))
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and



























































On the event E2, using the same type of argument as (2.16) with R = 2
jεn (given that

















where C ′ is a constant (because jn = [log2(nM)]+1 and n << Gn) and the result of Lemma
6 follows from (2.16) and (2.17) with C = 1 + C ′. 
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2.8.3 Supplement C: Additional Simulations
In Chapter 2.5, simulations are presented comparing the performance of GLiDeR, the two-
stage model averaged double robust estimator proposed by Cefalu et al. (2017) (which we
abbreviate as “MADR”), two standard doubly robust estimators – one using all covariates
(“saturated method”) and another which selects covariates via “backward selection” (p-stay
= 0.05) on the outcome model – and a non-doubly robust method using the adaptive lasso
on only the outcome model to select covariates and estimate the average causal effect for ten
scenarios (“Scenarios 1–10” presented in Chapter 2.5.1) with p = 10 covariates (independent
and correlated) and sample size n = 500. Additional simulation scenarios are presented here
exploring the effects of adjusting the number of covariates and sample size in Scenarios 1–9.
Ratio of mean squared error (MSEs) of the doubly robust average causal treatment
effect of GLiDeR, backward selection, MADR, and adaptive lasso (denominator) relative
to the saturated variable selection method (numerator) for 5 independent covariates and
sample size n = 500 and for 10 independent covariates and sample size n = 250 are shown
in Tables 2.4 and 2.5, respectively.
Table 2.4: Ratio of MSE (saturated model MSE / alternative method MSE) for each scenario
with independent data, 5 covariates, and sample size n = 500 over 1,000 Monte Carlo
datasets.
Scenario GLiDeR Backward Selection MADR Adaptive Lasso
MSE Ratio MSE Ratio MSE Ratio MSE Ratio
1 1.09 1.01 1.10 1.11
2 1.08 1.00 1.10 1.11
3 2.77 1.00 2.88 3.00
4 1.00 1.00 1.01 0.66
5 1.63 1.04 1.62 1.64
6 16.82 0.91 18.15 16.00
7 1.10 1.03 1.09 1.13
8 1.21 1.03 1.21 1.29
9 1.02 1.02 1.02 1.02
Bold indicates significant difference (5% significance level) between MSEs (testing
equality) from the saturated method (full model) vs. the alternative method using
the paired t-test.
The same results are shown for 25 independent covariates and sample size n = 500 in
Table 2.6, but results were not calculated for MADR due to the relatively large number
of covariates. The MSE ratios with 5 covariates (Table 2.4) are slightly smaller for all
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Table 2.5: Ratio of MSE (saturated model MSE / alternative method MSE) for each scenario
with independent data, 10 covariates, and sample size n = 250 over 1,000 Monte Carlo
datasets.
Scenario GLiDeR Backward Selection MADR Adaptive Lasso
MSE Ratio MSE Ratio MSE Ratio MSE Ratio
1 1.13 1.03 1.15 1.18
2 1.12 1.04 1.14 1.14
3 3.59 1.17 3.77 3.97
4 1.04 1.02 1.05 0.90
5 1.81 0.93 1.79 1.78
6 24.31 1.27 24.77 21.81
7 1.19 1.06 1.16 1.21
8 1.39 1.10 1.38 1.46
9 1.11 1.08 1.12 1.12
Bold indicates significant difference (5% significance level) between MSEs (testing
equality) from the saturated method (full model) vs. the alternative method using
the paired t-test.
Table 2.6: Ratio of MSE (saturated model MSE / alternative method MSE) for each scenario
with independent data, 25 covariates, and sample size n = 500 over 1,000 Monte Carlo
datasets.
Scenario GLiDeR Backward Selection Adaptive Lasso
MSE Ratio MSE Ratio MSE Ratio
1 1.13 1.12 1.15
2 1.18 1.17 1.20
3 3.57 3.49 4.06
4 1.06 1.06 0.98
5 1.94 1.80 1.89
6 24.71 9.41 22.30
7 1.23 1.11 1.25
8 1.45 1.34 1.53
9 1.13 1.11 1.15
Bold indicates significant difference (5% significance level) between MSEs (testing
equality) from the saturated method (full model) vs. the alternative method using
the paired t-test.
methods and scenarios compared to 10 covariates (Table 2.5 in main manuscript) as the
alternative methods (GLiDeR, backward selection, MADR, and adaptive lasso) are generally
more efficient than the saturated method when there are more irrelevant variables. This is
further seen for GLiDeR, adaptive lasso, and backward selection with 25 covariates (Table
2.6) as these methods obtain much greater MSE ratios for all scenarios than with 5 and 10
covariates. When the sample size is cut in half (n = 250) with 10 covariates (Table 2.5), the
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MSE ratios increase in nearly all scenarios for all alternative methods. In other words, the
MSE ratios are further away from 1 for all methods and scenarios when the sample size is
halved, which seems to suggest the gap in performance between methods is increased with
a smaller sample size. As in the main manuscript, the adaptive lasso only considers the
outcome model and under-selects an important confounder weakly related to the outcome
but strongly associated to the treatment in Scenario 4 and is less efficient than the saturated
method even with 25 covariates.
Results are presented below testing generalized cross-validation (GCV) and k-fold cross-
validation (kCV) for k = 2, 5, and 10 folds on the outcome model for Scenarios 1–10 with
10 independent covariates for Scenarios 1–9 and 100 independent covariates for Scenario 10
and a sample size of 500 for all scenarios. GCV is performed as discussed in Chapter 2.3.4
and k-fold cross-validation chooses the tuning parameter value λ∗ as the value λ yielding
the smallest average mean squared prediction error across the k test folds. Performance is
generally similar for all procedures, but GCV demonstrates the best performance overall
at estimating the causal treatment effect in these scenarios, and also has a computational
advantage over kCV (especially for larger k) as it requires the method to be computed only
once on the data. Consequently, we recommend using GCV over kCV for model selection.
Table 2.7: Comparison of tuning parameter selection procedures.
GCV 2-fold 5-fold 10-fold
Scenario MSE Bias SD MSE Bias SD MSE Bias SD MSE Bias SD
1 0.0081 0.00 0.09 0.0081 0.00 0.09 0.0081 0.00 0.09 0.0081 0.00 0.09
2 0.0090 0.00 0.09 0.0089 0.00 0.09 0.0090 0.00 0.10 0.0090 0.00 0.09
3 0.0085 0.00 0.09 0.0091 0.00 0.10 0.0094 0.00 0.10 0.0091 0.00 0.10
4 0.0100 0.00 0.10 0.0100 0.00 0.10 0.0100 0.00 0.10 0.0101 0.01 0.10
5 0.4008 -0.04 0.63 0.4368 -0.05 0.66 0.4371 -0.06 0.66 0.4433 -0.06 0.66
6 0.0958 0.00 0.31 0.1350 -0.01 0.37 0.1057 0.00 0.33 0.1275 0.00 0.36
7 0.7040 -0.05 0.84 0.7175 -0.05 0.85 0.7213 -0.05 0.85 0.7268 -0.05 0.85
8 0.0143 0.01 0.12 0.0141 0.01 0.12 0.0144 0.01 0.12 0.0143 0.01 0.12
9 0.0117 0.00 0.11 0.0117 0.00 0.11 0.0118 0.00 0.11 0.0118 0.00 0.11
10 0.0603 0.00 0.26 0.0638 -0.07 0.24 0.0644 -0.08 0.24 0.0906 -0.15 0.26
51
Table 2.8: Covariates selected (average across 1000 samples) by GLiDeR. Though p = 100
covariates are considered for Scenario 10, only results for the first two irrelevant variables
(X9 and X10) are shown here.
Scenario X1 X2 X3 X4 X5 X6 X7 X8 X9 X10
1 0.07 0.06 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.04
2 1.00 0.12 1.00 1.00 0.04 0.04 0.04 0.04 0.03 0.04
3 1.00 1.00 0.07 0.06 0.06 0.02 0.01 0.01 0.01 0.01
4 1.00 1.00 1.00 1.00 1.00 0.05 0.04 0.04 0.04 0.04
5 0.28 0.28 0.80 0.79 0.80 0.06 0.05 0.05 0.06 0.06
6 0.16 0.17 0.08 0.09 0.16 0.02 0.02 0.02 0.02 0.03
7 0.51 0.11 1.00 0.92 0.09 0.06 0.06 0.08 0.06 0.06
8 1.00 1.00 0.59 0.06 0.06 0.05 0.04 0.05 0.05 0.06
9 1.00 0.06 1.00 1.00 0.04 0.05 0.04 0.06 0.05 0.06
10 1.00 0.99 1.00 1.00 0.21 0.20 0.21 0.19 0.01 0.01
Table 2.9: Bootstrap 95% percentile confidence interval coverage rates by GLiDeR for all
scenarios with sample size n = 500 and p = 10 covariates (except Scenario 10, which has
p = 100 covariates) across 1, 000 Bootstrap samples. Note that correlated covariates are
not considered for Scenario 10.
Scenario Independent Covariates Correlated Covariates












Table 2.10: Covariates (potential confounders) considered in the lung transplant registry.
Each variable is continuous or binary. The mean and standard deviation (if continuous) or
frequency and proportion (if binary) of each covariate for BLT and SLT is also shown.
BLT SLT
Mean (sd)/ Mean (sd)/
Name Description N (%) N (%)
Patient characteristics
AgeP Age (yrs) 63.6 (2.9) 64.2 (3.1)
BmiP Body Mass Index 24.5 (7.4) 24.8 (7.4)
DiabP Diabetes 64 (13%) 41 (9%)
HgtP Height (cm) 169.8 (9.1) 169.3 (9.3)
O2amt Oxygen delivered 4.07 (3.07) 3.43 (1.93)
Karn Karnofsky score > 60 155 (31%) 188 (42%)
LAS Lung allocation score 35.8 (7.6) 34.0 (3.6)
WhtP Race (white) 455 (92%) 416 (94%)
SexP Gender (female) 211 (43%) 208 (47%)
LifeS Life support ventilator needed 27 (5%) 4 (1%)
Vent Assisted ventilation needed 68 (14%) 49 (11%)
Vol Center volume 94.5 (66.5) 71.3 (45.8)
Walk 6 minute walking distance 746.7 (390.7) 719.2 (322.2)
O2rest Oxygen needed at rest 31 (6%) 36 (8%)
Donor characteristics
AgeD Age (yrs) 36.3 (14.4) 33.7 (14.4)
BlckD Race (black) 92 (19%) 87 (20%)
BmiD Body Mass Index 26.0 (5.2) 25.4 (4.9)
Cig History of cigarette use 74 (15%) 57 (13%)
CMV Positive cytomegalovirus (CMV) test 302 (61%) 266 (60%)
Cod Cause of death - traumatic brain injury 224 (45%) 243 (55%)
DiabD Diabetes 38 (8%) 24 (5%)
ExpD Expanded donor 65 (13%) 52 (12%)
HgtD Height (cm) 175.5 (9.4) 175.3 (9.2)
SexD Gender (female) 146 (30%) 135 (30%)
Dist Donor to treatment center distance 206 (243.8) 203.3 (246.9)
Po2 Lung PO2 387.2 (148.4) 364.5 (151.3)
Other characteristics
Allo Local or regional (vs. national) allocation 146 (30%) 114 (26%)
HgtR Height ratio 1.03 (0.05) 1.04 (0.05)
Isch Ischemic time 5.5 (1.6) 4.0 (1.4)
SexM Matching gender 125 (25%) 131 (30%)
RaceM Matching race 330 (67%) 274 (62%)
Chapter 3
Variable selection and estimation
in causal inference using Bayesian
spike and slab priors
3.1 Introduction
Inferring the causal effect of a treatment, exposure, or intervention (hereafter referred to
as “treatment”) on some outcome or response is often the primary goal of a study. Ran-
domizing treatment assignment is the gold standard for estimating causal treatment effects
but is unethical, infeasible, or not cost-effective in many situations. When treatment is not
randomized, confounding variables – those associated with both treatment and outcome –
can induce bias in the treatment effect estimator if ignored. There are many ways to adjust
for confounding variables; many approaches involve modeling the outcome as a function of
treatment and covariates or modeling the treatment as a function of covariates (or both).
Assuming all measured covariates contain all confounding variables, an unbiased estima-
tor of the causal treatment effect can be obtained from a model that correctly specifies the
conditional mean of the outcome as a function of treatment and covariates. Controlling for
all measured covariates prevents confounder omission and, therefore, protects against bias.
However, adjusting for covariates that are unrelated to the outcome can increase the vari-
ance of the treatment effect estimator without reducing bias, so the “all-inclusive” approach
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can be suboptimal for estimating treatment effects, especially when many measured covari-
ates are under consideration. Another approach is to use variable selection and adjust for
only the covariates that are related to the outcome (which includes confounding variables).
Traditional variable selection techniques, such as the lasso, select covariates based on their
associations in only the outcome model and may not select important confounding variables
that are weakly related to outcome but strongly associated with treatment. Using variable
selection on only the outcome (or treatment) model can, therefore, bias the treatment effect
estimator.
Bayesian model averaging (BMA) proposes taking a weighted average of the effect esti-
mates across models with different covariates included where the weights are determined by
the posterior model probability (Raftery, Madigan & Hoeting, 1997). However, like tradi-
tional variable selection, standard BMA tends to prioritize models which include covariates
strongly associated with outcome and may assign significant weight to models that include
only a subset of the necessary confounders, resulting in biased treatment effect estima-
tion (Crainiceanu, Dominici and Parmigiani, 2008). Crainiceanu, Dominici and Parmigiani
(2008) introduce a two-stage BMA method that forces strong predictors of treatment that
are identified in a first stage to be included in the outcome model in a second stage, and then
strong predictors of outcome that are not identified in stage one are identified in stage two.
Wang et al. (2012) propose Bayesian Adjustment for Confounding (BAC), a Bayesian model
averaging method on the outcome model with an informative prior obtained separately from
the treatment model (see Zigler and Dominici (2014) for related Bayesian methods that se-
lect variables for propensity score estimation). BAC contains a prior dependence parameter,
ω, ranging from 1 to ∞ that links the treatment model to the outcome model. If ω = ∞,
all covariates with associations in the treatment model are forced into the outcome model,
whereas ω = 1 treats the two models independently and is equivalent to standard BMA on
the outcome model.
Two approaches have been predominantly used to select ω: (1) setting ω equal to ∞ as
the default and (2) selecting ω data-adaptively to minimize mean squared error (MSE) or
other criterion. Each approach is problematic.
Setting ω = ∞ targets the set of covariates associated with treatment or outcome.
However, we observe that BAC with ω = ∞ can have high inclusion probabilities for
irrelevant covariates that are unrelated to outcome and treatment, particularly in smaller
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sample sizes. This can lead to inefficient estimators in moderate sample sizes compared to
other variable selection approaches which target the same set of covariates (i.e., all variables
associated with treatment or outcome). Furthermore, for a given sample size, selecting all
covariates related to treatment and outcome may not be the set which leads to the most
efficient estimator of the average causal effect. In Chapter 3.3.4, the variance and bias of
the treatment effect estimator is derived, and we find that adjusting for covariates that are
strongly related to treatment but unrelated (or very weakly related) to outcome can increase
the asymptotic variance of the treatment effect estimator without substantially reducing its
asymptotic bias. Consequently, to minimize MSE of the treatment effect estimator, it may
be necessary to use models which do not include covariates related only to treatment (or
those related to treatment but are very weakly related to the outcome) when estimating
the treatment effect.
However, developing a data-adaptive approach to select ω to minimize MSE has proved
challenging. Lefebvre, Atherton and Talbot (2014) proposed using cross validation or the
bootstrap to choose ω with the aim of minimizing MSE of the treatment effect estimator, but
they found that the performance of these procedures was sensitive to the underlying data
generating mechanism and suggested that alternative approaches should be investigated.
Even if cross validation or the bootstrap could be reliably used to choose ω, such methods
can be computationally intensive with large datasets. Further, BAC requires calculating the
Bayesian Information Criterion at each posterior draw, which cannot be calculated when
the number of potential confounders in the model exceeds the sample size.
In this chapter, we propose the Spike and Slab Causal Estimator (SSCE) and Bilevel
SSCE (BSSCE), novel Bayesian methods that simultaneously consider models for outcome
and treatment and use spike and slab priors on the covariate coefficients to encourage
variable selection based on associations in both the outcome and treatment models. SSCE
aims to minimize treatment effect bias by controlling only for covariates that are related to
outcome or treatment (and removing irrelevant ones), while BSSCE adjusts for the subset
of the covariates which minimize MSE of the treatment effect estimator. The proposed
methods, which are adapted from the formulation of the Bayesian group lasso with spike
and slab priors Xu and Ghosh (2015), are implemented using fast Gibbs samplers that
perform well with a large number of covariates, even when the number of covariates is
greater than the sample size.
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3.2 Preliminaries
3.2.1 Estimation of causal treatment effects
Suppose an observational study yields outcomes Y = {Y1, . . . , Yn} with corresponding bi-
nary treatment indicators A = {A1, . . . , An} for independent subjects 1, . . . , n, and we are
interested in estimating the average causal effect of a binary treatment A on outcome Y ,
defined as
∆ = E{Y (1)− Y (0)},
where Y (1) and Y (0) denote potential outcomes that would be observed from an arbitrary
individual in the population if given treatment (A = 1) and control (A = 0), respectively.
Other measures of the causal treatment effect, such as the average effect of treatment on
the treated, could also be applied here. If we are willing to assume consistency and strong
ignorability, i.e., that measured covariates X = X1, . . . , Xp include all confounding variables
so that {Y (0), Y (1)} ⊥ A|X, then
E{E(Y |A = 1,X)} = E[E{Y (1)|A = 1,X}] = E[E{Y (1)|X}] = E{Y (1)},
and similarly, E{E(Y |A = 0,X)} = E{Y (0)}. This implies ∆ = E{E(Y |A = 1,X) −
E(Y |A = 0,X)}, so a correctly specified model for E(Y |A,X) can be used to consistently
estimate ∆. If we assume a linear regression model for E(Y |A,X),
Yi|Xi, Ai, β, σ2 ∼ N{µ(Xi, Ai, β), σ2}, i = 1, . . . , n, (3.1)
where
µ(Xi, Ai;β) = β0 + βAAi + β
TXi,






{µ(Xi, Ai = 1; β̂)− µ(Xi, Ai = 0; β̂)} = β̂A.
It is common to adjust for all measured covariates X when estimating βA. Assuming X
contains all confounding variables, adjusting for all measured covariates ensures adjustment
for all confounders, which protects against bias in the treatment effect estimator that could
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otherwise emerge if a confounder is omitted. But since adjusting for measured covariates
that are unrelated to E(Y |A,X) can increase the variability of the treatment effect estimator
without reducing its bias, some type of dimension reduction to select covariates associated
with E(Y |A,X) is necessary to achieve unbiased, efficient estimation of βA.
3.2.2 Bayesian spike and slab lasso (BSSL)
The lasso Tibshirani (1996) is a popular variable selection technique that can perform well
when p is large, possibly even greater than n. Though the standard Bayesian lasso shrinks
covariate coefficients toward zero, it does not yield posterior estimates that are exactly zero.
Xu and Ghosh (2015) use spike and slab priors on the model coefficients to propose the
Bayesian Spike and Slab Lasso (BSSL), a hierarchical formulation of the Bayesian lasso that
allows draws from the posterior of each covariate coefficient to be exactly zero. Particularly,
the prior on β is
βj |σ2, τ2j
ind.∼ (1− π0)N(0, σ2τ2j ) + π0δ0(βj), j = 1, . . . , p,
where δ0() is a point mass at zero and π0 is the prior probability that a covariate coefficient
is zero; conjugate priors can be used for σ2 (Inverse Gamma), π0 (Beta), and τ
2
j (Gamma).
These priors control the amount of shrinkage of the covariate coefficients. Throughout, we
assume covariates X are standardized to have marginal mean zero and unit variance so that
covariate selection is invariant to the scale of the covariates.
BSSL can be used to select variables for µ(X, A;β) and simultaneously estimate βA, but
it ignores the relationship between covariates and treatment. There are no problems using
BSSL asymptotically, but in finite samples, BSSL may not select important confounding
variables that are weakly related to the outcome, even if they are strongly associated with
the treatment. The next section proposes a novel framework that aims to reduce bias in
finite samples by encouraging selection of covariates that are associated with treatment
assignment.
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3.3 Spike and slab causal estimation methodology
3.3.1 Simultaneous modeling of outcome and treatment
We begin by specifying a probit model for the conditional probability that subject i receives
treatment (Ai = 1),
P (Ai = 1|Xi) = Φ(γ0 + γTXi),
where Φ() is the cumulative distribution function of a standard normal random variable.
An equivalent formulation of the probit model states that there exists A∗i such that Ai = 1
if A∗i > 0 and Ai = 0 if A
∗
i ≤ 0, where A∗i is an unobserved (latent) variable that is normally
distributed with mean γ0 +γ
TXi and unit variance. Such an assumption allows us to model
A∗ in the way that Y is modeled in BSSL, but without the term for the treatment effect,
βA.
To select covariates based on their associations with both outcome and treatment assign-
ment, we define a new vector O = (Y,A∗)T by stacking the outcomes and latent treatment





consisting of the design matrices Xout = {1n,A,X1, . . . ,Xp} for the outcome model and
Xtrt = {1n,X1, . . . ,Xp} for the treatment model. We note that Z contains two columns
that are associated with each covariate, a crucial fact for the joint selection technique we
introduce in the next section. With this notation, the likelihood can be written as
O|Z, α, σ2 ∼ N2n(Zα,ΣO), (3.2)
with α = (β0, βA, β1, . . . , βp, γ0, γ1, . . . , γp)
T and ΣO a 2n × 2n diagonal matrix with σ2 as
the first n elements of the diagonal and 1 as the last n elements of the diagonal.
The variable selection techniques which we propose use a modified Bayesian group lasso
approach. The group lasso is an extension of the lasso to allow selection of predetermined
groups of variables (Yuan and Lin, 2006). For example, if Xi and Xj were related in such a
way that we would want to include or exclude both variables simultaneously in the model,
we could use the group lasso and group together the regression coefficients that correspond
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to Xi and Xj (βi and βj); then after grouping the other p − 2 coefficients in the model so
that all p coefficients belong to exactly one group, the group lasso will force all coefficients
in a group will be either all zero or all nonzero, meaning βi and βj will simultaneously
be zero or nonzero. If all groups are of size one, the group lasso and lasso estimators are
equivalent.
For our problem, we have two models (one for outcome and one for treatment assign-
ment) and want each covariate to be included or excluded simultaneously from both models
(i.e., want βj and γj to be both zero or both nonzero). That is, we want the coefficients
in the model for O|Z, α, σ2 corresponding to the covariates (XTj ,0) and (0,XTj ) to be in-
cluded or excluded simultaneously. We, therefore, use the idea of the group lasso to form p
groups of size 2, with each group k containing the outcome and treatment model coefficients
corresponding to covariate k (as in Chapter 2):
Group 1 = {β1, γ1},Group 2 = {β2, γ2} . . . ,Group p = {βp, γp}.
3.3.2 Spike and slab causal estimator (SSCE)
Using a similar idea to the Bayesian spike and slab group lasso proposed by Xu and Ghosh
(2015) (an extension of BSSL), we propose the following prior with the likelihood in (3.2):
 βj
γj











 , j = 1, . . . , p.
As in Xu and Ghosh (2015), conjugate priors are used for σ2 (Inverse Gamma) and π0
(Beta), the prior probability that (βj , γj)
T = (0, 0)T . Flat priors are used for β0, βA, and γ0
since we do not want to shrink these coefficients toward zero. We also recommend setting
τ2j to a large enough positive value so that the Normal slab on the covariate coefficients
is effectively non-informative (we used τ2j = 1000 for all j in our simulations; see Chapter
3.3.3 for more details). To implement this model, which we call the Spike and Slab Causal
Estimator (SSCE), a fast Gibbs sampler is used to generate samples from the posterior
distribution of the treatment effect βA and other parameters (after standardizing covari-
ates); all priors are conjugate, so full conditionals are easily derived and implemented. The
full conditionals used in the Gibbs samplers are given in Chapter 2.8.1, and R code for
implementation of SSCE (and BSSCE, which is proposed in Chapter 3.3.4) is available at
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https://github.com/drbkoch/SSCE.
3.3.3 A motivating example for SSCE and choice of τ 2j
In Chapter 3.7.2, a simplified example is presented to illustrate the properties and behavior
of SSCE. Figure 3.1 plots the posterior probability that βj is zero for this example as a
function of its least squares estimate (β̂lsj ) using BSSL (represented by the black line) and
SSCE; the posterior probability βj is zero using SSCE depends on the magnitude of the
maximum likelihood estimate of γj under the full model (denoted γ̂j), and each colored line
represents a different value of this estimate using SSCE.
As γ̂j is increased, the posterior probability that βj is zero decreases and eventually
reaches zero, thereby increasing the inclusion probability of confounders in SSCE. Addition-
ally, when covariate j is irrelevant (i.e., β̂lsj and γ̂j are near zero), the posterior probability
βj is zero is larger with SSCE, meaning irrelevant covariates will be selected less frequently
with SSCE compared to BSSL.
The posterior distribution of βj for fixed τ
2
j is also derived for the simplified example
presented in Chapter 3.7.2. There is a finite-sample bias for βj , with magnitude equal to
β̂lsj
1+nτ2j
, that may increase bias in our estimator for the treatment effect, β̂A. To remedy such
a problem, we set each τ2j to a common large value that makes the bias negligible in the
estimates of each covariate coefficient and minimized shrinkage to zero.
3.3.4 Bilevel spike and slab causal estimator (BSSCE)
Adjusting for covariates that are strongly related to treatment but unrelated to outcome
may increase the variance of the treatment effect estimator without reducing its bias. The
asymptotic variance of the least squares treatment effect estimator (i.e., β̂A) with covariates
X−j , where X−j is the vector of covariates excluding the jth covariate, is






and with covariates X−j and covariate Xj , the asymptotic variance is
Varβ̂A(βj , γj ; X−j , Xj) =
1
n
σ2Y |A,X−j − σ
2










Figure 3.1: P (βj = 0|O,Z) as a function of the least squares estimate of βj under orthogonal
outcome and treatment design matrices. The colors denote the posterior probability βj is
zero using the proposed method for different values of γ̂j ; purple, blue, green, orange,
yellow, and red (i.e., from top to bottom of figure at least squares estimate of βj equal to
0) respectively represent γ̂j equal to 0.05, 0.10, 0.15, 0.20, 0.25, and 0.30. The black line
denotes the posterior probability βj is zero under BSSL. For this Figure, n = 250, π0 = 0.5,
σ2 = 1, and τ2j = 1.
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where σ2L|R denotes the residual variance when fitting a linear model on L with covariates
R, and βj is the true coefficient corresponding to covariate Xj in the outcome and ηj is
the coefficient corresponding to Xj from regressing A on X using a linear model. The
asymptotic bias of β̂A with covariates X−j (and Xj excluded) is




Note that because we assume that we have measured all confounders, the bias with covari-
ates X−j and Xj is 0. Using a first-order Taylor series expansion and assuming that Xj is
normally distributed, ηj can be approximated
γj√
2π
. We use this approximation throughout.
Adjusting for covariate Xj that is unrelated to outcome (i.e., with small |βj |) but strongly
associated with treatment (i.e., with large |γj |) will have a small change in bias (no change
if βj = 0) but potentially large increase in variance.
To reduce MSE (equal to the variance plus the square of the bias) of the treatment effect
estimator, we propose BSSCE, which has the following spike and slab prior on each group
of coefficients:  βj
γj





where D is a two-dimensional distribution with density function f(βj , γj) that is equal to
the density of the normally distributed slab in SSCE except for values (βj , γj) such that
Varβ̂A(βj , γj ; X−j)−Varβ̂A(βj , γj ; X−j , Xj) + Biasβ̂A(βj , γj ; X−j)
2 < 0,
where the density is set to zero. That is, values of βj , γj for which MSE would be lower if
βj and γj were set to zero (covariate j were removed from the model) are not included in
the support. Instead, we include point mass at βj = 0 and γj = 0 to ensure that f(βj , γj) is
a valid density. We call this a bi-level model because it is reminiscent of the bi-level group
lasso proposed by Xu and Ghosh (2015), in which selection is first done between and then
within groups. At the first level, the spike in the prior (δ0) removes covariates irrelevant
to both treatment and outcome as in SSCE. However, in BSSCE the second “level” of
selection is still at the group level, but specifically reduces MSE. This “level” of selection
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occurs within the part of the prior denoted by D here. The result of the restricted support
is to shrink any βj , γj on covariates whose inclusion in the model increase the MSE (due to
weak association with outcome) to zero, as indicated by the second point mass described
above. Coefficients that are equal to zero using SSCE are also zero using BSSCE. However,
coefficients that are non-zero for SSCE may be zero for BSSCE. Computationally, BSSCE
uses the same Gibbs sampler as SSCE, except BSSCE implements a second stage that sets
non-zero coefficient values from SSCE which increase MSE to zero.




Xj |A,X−j , and σ
2
Xj |X−j .
To estimate σ2Y |A,X−j , the standard lasso estimator, call it β̂
lasso, is obtained for the coeffi-
cients in the regression of X and A on Y . Our estimate of σ2Y |A,X−j for all covariates j such










(Yi − β̂lasso0 − β̂lasso1 X1i − · · · − β̂lassop Xpi − β̂lassoA Ai)2.
Next, the lasso estimator for the coefficients in the regression of X−j and A on Y is obtained


















Such an estimation technique is computationally inexpensive and allows for estimation when
p is greater than n.
The probit model used for the treatment assignment assumes there exists a latent vari-
able (which determines the treatment assignment indicator) with a linear mean and unit
error variance. This latent variable (called A∗ in Chapter 3.3.1) can be viewed as the treat-
ment assignment on a continuous scale, in which case σ2A|X (the error variance assuming
treatment assignment follows a linear regression model as a function of X) would approx-
imately equal one. We, therefore, use σ̂2A|X−j = 1 for all j. Similarly, assuming covariates
are independent and not caused by the treatment, then since covariates are standardized
to have unit variance, we use σ̂2Xj |A,X−j = 1 and σ̂
2
Xj |X−j = 1. These parameter estimates
performed well in simulations, even when covariates were not independent.
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Figure 3.2: P (βj = 0|rest) as a function of a and b with large slabs (i.e., τ2j large), where a
and b are proportional to the correlation between the jth covariate and the residual vectors
without the jth covariate in the outcome and treatment models, respectively. For this
figure, n = 250, π0 = 0.5, and σ
2 = 1.
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3.3.5 Covariate inclusion probability for SSCE and BSSCE
In Chapter 3.7.3, the conditional probability that βj (and γj) is zero under SSCE is derived
assuming only that covariates are standardized (as in Chapter 3.2.2). Figure 3.2 plots this
probability as a function of a and b, where a and b are proportional to the correlation be-
tween the jth covariate and the residual vectors without the jth covariate in the outcome
and treatment models, respectively. The probability βj is zero decreases as a function of
a2
σ2
+ b2, meaning βj is less likely to be zero if covariate j has stronger associations with the
residuals in the outcome or treatment model. Thus, SSCE is more likely than BSSL to in-
clude confounders with weak associations to outcome but strong associations to treatment,




+b2 will have small probability of having non-zero coefficients, meaning the variabil-
ity in the estimator for βA should be reduced using SSCE compared to a model that adjusts
for such irrelevant covariates. However, covariates that are strongly related to treatment
will always be included when using SSCE, even if they are unrelated to outcome. BSSCE,
on the other hand, allows covariates only related to treatment to have inclusion probability
less than one, which can be seen in Figure 3.2, where covariate inclusion probabilities are
derived for BSSCE as functions of a and b using Monte Carlo integration.
3.4 Simulations
Table 3.1: Covariates X1, . . . , Xp are generated with mean µx and variance Vx, where
Cor(Xi, Xj) = ρ for i 6= j, i, j ≤ 20. and Cor(Xi, Xj) = 0 for i 6= j, i, j > 20, and
treatment indicators and corresponding outcomes are generated from Bernoulli(expit(µA))
and Normal(µY , VY ), respectively, where expit(x) =
exp(x)
1+exp(x) , for the following scenarios.
Scenario µx Vx ρ µA µY VY
1 1 4 0 0.2X1 − 2X2 +X5 −X6 +X7 −X8 2X1 + 0.2X2 + 5X3 + 5X4 4
2 0 1 0.5 −2X1 − 2X2 − 2X3 +X4 +X5−
∑9
j=1 0.2Xj + 0.5X10 − 5X11 − 5X12 1
0.2X6 + 2X7 +X8 − 0.5X9 +X10
3 0 1 0.5 −2X1 − 2X2 − 2X3 +X4 +X5 − 0.2X6+
∑9
j=1 0.2Xj + 0.5X10 − 5X11 − 5X12 1




To evaluate the performance of SSCE and BSSCE, we considered three different data-
generating scenarios described in Table 4.1. In Scenario 1, covariates are independent, and
there is a single confounder that is weakly associated with the outcome and strongly related
to the treatment (X2). In Scenarios 2 and 3, the covariates are correlated, and there are
multiple confounders weakly associated with outcome. There are no covariates related to
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treatment but unrelated to outcome in Scenario 2, while in Scenario 3, some covariates
(X13, . . . , X16) are related to treatment but not outcome. We vary the sample size in all
scenarios and vary the number of irrelevant covariates in Scenario 1.
We compare SSCE and BSSCE to BSSL – with τ2j = 1000 to remove shrinkage bias –
and to BAC with ω = ∞. We used Inverse Gamma(0.1, 0.1) and Beta(1, 1) distributions
as priors for σ2 and π0, respectively, in the simulation. Standard R programming was used
to implement SSCE, BSSCE, and BSSL, while the R package bacr was used to implement
BAC. Note that treatment indicators are generated according to a logistic regression model
as assumed in the analysis by BAC but not by the other methods, which instead posit a
probit model for treatment assignment.
Simulations are replicated over 500 Monte Carlo (MC) samples, and 5,000 Markov Chain
MC samples were used per chain for each method, where the MC standard error for these
chain lengths was estimated (using the R package mcmcse) to range from approximately
0.005-0.01. To compare variable selection performance, the probability of inclusion for each
covariate is calculated as the proportion of posterior draws for which its outcome regression
coefficient is non-zero. The MC bias, standard error, and MSE of the treatment effect
estimator are calculated for each method using the posterior mean of βA. 95% credible
intervals for the treatment effect are estimated for each method using the 2.5% and 97.5%
quantiles of the posterior distribution of βA. Code to reproduce the simulation is available
at https://github.com/drbkoch/SSCE.
Table 4.2 shows the average inclusion probabilities for the first ten covariates in Scenario
1 for different sample sizes (n) and total number of covariates (p). Using the Bayesian lasso
on the outcome model with spike and large slab priors (BSSL with fixed large τ2j ), the
average inclusion probability for the confounder weakly related to outcome (X2) is near
zero for all considered combinations of n and p, except with the largest ratio of n to p
(n = 500, p = 50), where the inclusion probability for X2 is 0.37. Using SSCE, however,
yields an average inclusion probability close or equal to one for the weak confounder for all
considered n and p. Average inclusion probabilities of the weak confounder are similar using
BAC compared to SSCE. However, the average inclusion probabilities of irrelevant covariates
are approximately zero using SSCE, even with twice as many covariates as subjects (n =
250, p = 500), and much smaller compared to those of BAC.
By including irrelevant covariates less frequently, SSCE decreases the variability and
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Table 3.2: Covariate inclusion probabilities in Scenario 1 for the first 10 covariates under
numerous combinations of n (sample size) and p (number of covariates). X1 is a confounder
strongly associated with outcome and weakly associated with treatment; X2 is a confounder
weakly associated with outcome, X5 −X8 are only associated with treatment, and X9 and
X10 are irrelevant.
Weak Only Related Only Related
Confounder Confounder to Outcome to Treatment Irrelevant
X1 X2 X3 X4 X5 X6 X7 X8 X9 X10
n = 100, p = 50
BSSL 1 0.02 1 1 0 0 0 0 0 0
BAC 1 0.95 1 1 0.83 0.80 0.83 0.82 0.34 0.34
SSCE 1 0.88 1 1 0.09 0.08 0.09 0.13 0 0
BSSCE 1 0.41 1 1 0 0 0 0.01 0 0
n = 150, p = 50
BSSL 1 0.04 1 1 0 0 0 0 0 0
BAC 1 1 1 1 0.89 0.89 0.90 0.91 0.40 0.41
SSCE 1 1 1 1 0.40 0.37 0.39 0.43 0 0
BSSCE 1 0.71 1 1 0.02 0.01 0.01 0.02 0 0
n = 200, p = 50
BSSL 1 0.06 1 1 0 0 0 0 0 0
BAC 1 1 1 1 0.96 0.97 0.93 0.96 0.45 0.46
SSCE 1 1 1 1 0.77 0.76 0.77 0.78 0 0
BSSCE 1 0.85 1 1 0.03 0.03 0.03 0.03 0 0
n = 250, p = 50
BSSL 1 0.08 1 1 0 0 0 0 0 0
BAC 1 1 1 1 1 1 0.99 1 0.51 0.50
SSCE 1 1 1 1 0.94 0.94 0.94 0.94 0 0
BSSCE 1 0.91 1 1 0.06 0.05 0.06 0.05 0 0
n = 500, p = 50
BSSL 1 0.37 1 1 0 0 0 0 0 0
BAC 1 1 1 1 1 1 1 1 0.10 0.12
SSCE 1 1 1 1 1 1 1 1 0 0
BSSCE 1 0.98 1 1 0.25 0.25 0.25 0.28 0 0
n = 250, p = 100
BSSL 1 0.06 1 1 0 0 0 0 0 0
BAC 1 1 1 1 1 1 1 1 0.10 0.12
SSCE 1 1 1 1 0.77 0.76 0.77 0.77 0 0
BSSCE 1 0.91 1 1 0.05 0.04 0.05 0.04 0 0
n = 250, p = 250
BSSL 1 0.04 1 1 0 0 0 0 0 0
BAC * * * * * * * * * *
SSCE 1 1 1 1 0.66 0.66 0.67 0.67 0 0
BSSCE 1 0.91 1 1 0.04 0.03 0.04 0.03 0 0
n = 250, p = 500
BSSL 1 0.02 1 1 0 0 0 0 0 0
BAC * * * * * * * * * *
SSCE 1 1 1 1 0.59 0.56 0.57 0.57 0 0
BSSCE 1 0.91 1 1 0.03 0.02 0.03 0.02 0 0
*Too many covariates for BAC
MSE of the treatment effect estimator compared to BAC for all considered combinations
of n and p in Scenario 1 except the largest considered ratio of n to p (n = 500 and p =
50), where the variability and MSE of the treatment effect estimator are similar between
BAC and SSCE (see Table 4.3). BSSCE, which aims to reduce MSE of the treatment
effect estimator, leads to much smaller inclusion probabilities for covariates related only
to treatment in Scenario 1 compared to SSCE and BAC, and nearly identical inclusion
probabilities for irrelevant covariates as SSCE. Though the weak confounder is selected less
often with BSSCE than with SSCE and BAC in Scenario 1, BSSCE still achieves similar
95% CI coverage of the treatment effect as SSCE and BAC, and yields a significantly smaller
MSE of the treatment effect than all considered methods for all considered ratios of n to
p (except n = 100 and p = 50 - the smallest ratio - where BSSCE and SSCE perform
similarly).
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Table 3.3: MC Bias, standard error (SE), MSE, and 95% credible interval (CI) coverage
probability for the treatment effect estimators.
Bias SE MSE 95% CI Coverage
Scenario 1
n = 100, p = 50
BSSL -0.419 0.438 0.367 0.826
BAC -0.059 0.741 0.551 0.904
SSCE -0.025 0.554 0.307 0.934
BSSCE -0.160 0.532 0.308 0.918
n = 150, p = 50
BSSL -0.403 0.373 0.301 0.782
BAC 0.005 0.566 0.320 0.938
SSCE 0.014 0.475 0.226 0.952
BSSCE -0.041 0.434 0.189 0.938
n = 200, p = 50
BSSL -0.393 0.323 0.258 0.722
BAC 0.019 0.461 0.213 0.942
SSCE -0.000 0.424 0.179 0.968
BSSCE -0.014 0.360 0.130 0.950
n = 250, p = 50
BSSL -0.373 0.308 0.234 0.694
BAC 0.023 0.421 0.177 0.928
SSCE 0.009 0.395 0.156 0.958
BSSCE 0.001 0.328 0.107 0.954
n = 500, p = 50
BSSL -0.232 0.291 0.138 0.754
BAC 0.022 0.292 0.085 0.956
SSCE 0.014 0.291 0.085 0.946
BSSCE -0.002 0.240 0.058 0.962
n = 250, p = 100
BSSL -0.389 0.297 0.239 0.674
BAC 0.041 0.431 0.187 0.936
SSCE 0.009 0.386 0.149 0.944
BSSCE 0.000 0.327 0.107 0.950
n = 250, p = 250
BSSL -0.403 0.285 0.244 0.648
BAC * * * *
SSCE 0.007 0.378 0.142 0.946
BSSCE -0.001 0.325 0.105 0.950
n = 250, p = 500
BSSL -0.410 0.281 0.247 0.646
BAC * * * *
SSCE -0.000 0.369 0.136 0.948
BSSCE 0.002 0.318 0.101 0.944
Scenario 2
n = 100, p = 30
BSSL -0.233 0.455 0.260 0.916
BAC 0.002 0.657 0.431 0.934
SSCE -0.141 0.477 0.247 0.950
BSSCE -0.179 0.463 0.246 0.942
n = 250, p = 30
BSSL -0.248 0.308 0.156 0.864
BAC -0.026 0.363 0.132 0.938
SSCE 0.009 0.353 0.125 0.954
BSSCE -0.100 0.311 0.107 0.946
n = 500, p = 30
BSSL -0.256 0.258 0.132 0.754
BAC -0.012 0.256 0.066 0.950
SSCE -0.011 0.261 0.068 0.956
BSSCE -0.001 0.260 0.067 0.958
Scenario 3
n = 100, p = 30
BSSL -0.196 0.438 0.230 0.912
BAC -0.024 0.666 0.443 0.944
SSCE -0.158 0.439 0.217 0.930
BSSCE -0.173 0.436 0.220 0.932
n = 250, p = 30
BSSL -0.175 0.296 0.118 0.888
BAC 0.035 0.399 0.160 0.944
SSCE -0.044 0.358 0.130 0.928
BSSCE -0.079 0.300 0.096 0.930
n = 500, p = 30
BSSL -0.153 0.216 0.070 0.894
BAC 0.011 0.268 0.072 0.940
SSCE 0.039 0.273 0.076 0.942
BSSCE -0.022 0.212 0.046 0.954
*Too many covariates for BAC
In Scenario 2, where covariates are correlated and there are numerous weak confounders,
the BSSL estimator is biased, as expected, and yields the largest MSE of all methods for
scenarios where n = 250 and n = 500. The bias using SSCE is much larger than that
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of BAC with n = 100. In this situation, the inclusion probabilities for the confounding
variables are larger using BAC compared to SSCE (and larger for SSCE compared to BSSL).
However, BAC displays much larger inclusion probabilities for irrelevant variables and much
larger variability in the treatment effect estimator compared to the other methods, and
consequently has the largest MSE of all methods when n = 100 and p = 30. Even with bias,
SSCE still achieves treatment effect credible interval coverage probability at the nominal
level, even larger than BAC. When the sample size is increased to n = 250, the MSE
using SSCE is still smaller than that of BAC, and BSSCE obtains the smallest MSE of
all methods. With n = 500, the MSEs using SSCE, BSSCE, and BAC are similar, which
is expected since there are no covariates strongly related to treatment but unrelated (or
very weakly related) to outcome. That is, SSCE, BSSCE, and BAC all target the same
set of covariates in Scenario 2, so we would expect that with moderate sample size their
performance would be similar.
In Scenario 3, which is similar to Scenario 2 except that there are covariates directly
related to treatment but not directly related to outcome, SSCE reduces the MSE of the
treatment effect estimator over BSSL and BAC for all sample sizes considered, except with
n = 500 where SSCE and BAC achieve a similar MSE. BSSCE yields a similar MSE to
SSCE with n = 100, and a significantly smaller MSE than the other methods with n = 250
and n = 500 because BSSCE includes those covariates which are only related to treatment
(which lead to increased variance of the treatment effect estimator but no difference in bias)
with much lower probability.
3.5 Application
In critical care resolving hypotensive episodes (HEs) in a timely manner is crucial to min-
imizing end organ damage (Lee et al., 2012). The procedures for treating HEs vary, and
there is evidence that certain treatments could be associated with a shorter HE duration for
patients in critical care (Lee et al., 2012). Data on patients treated in intensive care units
(ICUs) were obtained from the publicly available Multi-parameter Intelligent Monitoring
in Intensive Care III (MIMIC-III) database to infer the average causal effect of fluid resus-
citation compared to vasoactive therapy on HE duration. MIMIC-III contains descriptive
de-identified clinical data (demographics, vital signs, laboratory tests, medications, etc.)
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from approximately 50,000 adult patients admitted to critical care units at the Beth Israel
Deaconess Medical Center in Boston, Massachusetts between 2001 and 2012 (Johnson et
al., 2016).
Patients from the MetaVision data management system were included in the analyses
if they experienced a HE, which was defined based on mean arterial pressure (MAP) mea-
surements generally recorded every 10-15 minutes, and received vasoactive therapy or fluid
resuscitation. Following Lee et al. (2012) the beginning of a HE was defined as the time
of two consecutive MAP measurements ≤ 60mm Hg, preceded by two consecutive MAP
measurements > 60mm Hg. The end of a HE was then defined as the first time that two
consecutive MAP measurements > 60mm Hg. Only data on the first HE for each sub-
ject was collected so that observations are independent. Vasoactive therapy was defined as
an initiation or a dosage increase of dobutamine, dopamine, epinephrine, norepinephrine,
phenylephrine or vasopressin during the HE. Fluid resuscitation was defined as at least one
infusion of either any volume of colloids or a bolus of isotonic crystalloid.
Table 3.4: Covariates considered in the application. For continuous covariates, the mean
and standard deviation (SD) by treatment status is provided, and for categorical covari-
ates, the number observed (N) and percentage (%) by treatment status is given. Inclusion
probabilities for SSCE, BSSCE, BSSL, and BAC are also shown.
Vasoactive therapy Fluid resuscitation
Mean/N Mean/N Inclusion probabilities
(SD/%) (SD/%) SSCE BSSCE BSSL BAC
Mean MAP 3hrs prior to treatment 68.0 (9.6) 66.1 (6.8) 1 1 0.999 1
SAPSII 72.1 (14.1) 64.7 (14.5) 1 0.662 0.001 1
MAP at treatment 56.4 (13.3) 58.1 (11.5) 0 0 0.013 0.885
Liver disease 66 (9.4%) 39 (20.0%) 0 0 0 0.653
Surgical ICU 209 (29.7%) 68 (34.9%) 0 0 0 0.520
Cardiac Surgery Recovery Unit 92 (13.1%) 33 (16.9%) 0 0 0 0.356
Creatinine value 1.6 (1.5) 1.4 (1.3) 0 0 0.001 0.297
Alcohol abuse 53 (7.5%) 24 (12.3%) 0 0 0 0.190
Hypothyroidism 90 (12.8%) 28 (14.4%) 0 0 0 0.160
Medical ICU 79 (11.2%) 7 (3.6%) 0 0 0 0.145
Rheumatoid arthritis 24 (3.4%) 9 (4.6%) 0 0 0 0.142
Age 66.7 (13.7) 65.5 (16.0) 0 0 0 0.125
Sex 428 (60.9%) 107 (54.9%) 0 0 0 0.108
Blood anemias 5 (0.7%) 5 (2.6%) 0 0 0 0.103
Peripheral vascular disorders 75 (10.7%) 18 (9.2%) 0 0 0 0.088
Congestive heart failure 210 (29.9%) 46 (23.6%) 0 0 0 0.085
Renal failure 33 (4.7%) 7 (3.6%) 0 0 0.001 0.084
Paralysis 11 (1.6%) 4 (2.1%) 0 0 0 0.083
Fluid and electrolyte disorders 341 (48.5%) 80 (41.0%) 0 0 0 0.079
Chromic pulmonary disease 167 (23.8%) 36 (18.5%) 0 0 0 0.070
Coronary Care Unit 93 (13.2%) 28 (14.4%) 0 0 0 0.063
Weight loss 46 (6.5%) 16 (8.2%) 0 0 0 0.060
AIDS 3 (0.4%) 1 (0.5%) 0 0 0 0.060
Valvular disease 158 (22.5%) 42 (21.5%) 0 0 0 0.053
Other neurological disorders 74 (10.5%) 14 (7.2%) 0 0 0 0.050
Urine output 3hrs prior to treatment 39.6 (693.8) 17.5 (184.0) 0 0 0 0.050
Diabetes, uncomplicated 182 (25.9%) 48 (24.6%) 0 0 0 0.050
Cardiac arrhythmias 284 (40.4%) 74 (37.9%) 0 0 0 0.048
Drug abuse 25 (3.6%) 10 (5.1%) 0 0 0 0.047
Solid tumor without metastasis 101 (14.4%) 22 (11.3%) 0 0 0 0.047
Lymphoma 17 (2.4%) 4 (2.1%) 0 0 0 0.043
Diabetes, complicated 49 (7.0%) 11 (5.6%) 0 0 0 0.040
Psychoses 29 (4.1%) 9 (4.6%) 0 0 0 0.038
Coagulopathy 162 (23.0%) 49 (25.1%) 0 0 0 0.037
Hypertension, uncomplicated 327 (46.5%) 91 (46.7%) 0 0 0 0.028
Peptic ulcer disease excluding bleeding 12 (1.7%) 6 (3.1%) 0 0 0 0.024
Deficiency anemias 137 (19.5%) 35 (17.9%) 0 0 0 0.020
Pulmonary circulation disorders 71 (10.1%) 24 (12.3%) 0 0 0 0.015
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Figure 3.3: Estimated posterior distributions of βA (causal effect of fluid resuscitation vs.
vasoactive therapy on HE duration in minutes, log-transformed) for each method.
The potential confounders are described in Table 4.4. After removing cases with missing
covariate values, n = 898 observations remained in the analyses with p = 38 potential
confounders. The outcome of interest was time from treatment to the end of the HE (in
minutes and log-transformed). Because these data involve human subjects, the data use
agreement does not permit the authors to directly release or archive the data but it may be
requested from https://mimic.physionet.org/; code to reproduce these analyses is available
from https://github.com/drbkoch/SSCE
Figure 3.3 shows the estimated posterior distribution of βA (A = 1 if vasoactive therapy
is used and A = 0 if fluid resuscitation is used) using SSCE, BSSCE, BSSL with fixed large
τ2j , and BAC. All methods yield credible intervals (using the 0.025 and 0.975 quantiles of
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the posterior distribution of βA) that contain zero, indicating no significant difference in HE
duration for patients receiving vasoactive therapy compared to fluid resuscitation. Using
SSCE, the estimated posterior mean of βA is -0.09 (95% credible interval = (-0.27, 0.09)),
while the estimated posterior mean of βA using BSSCE is -0.11 (95% credible interval = (-
0.30, 0.08)). The estimated posterior mean of βA using BSSL is -0.14 (95% credible interval
= (-0.32, 0.04)), while BAC estimates the posterior mean of βA to be -0.10 (95% credible
interval = (-0.27, 0.09)).
We can see from Table 4.4 that many more covariates have non-zero inclusion probabil-
ity when using BAC compared to the spike and slab methods, which is consistent with our
simulation results. The SAPSII score, which estimates severity of disease, has its outcome
coefficient equal to zero in nearly all posterior samples when using BSSL, but has a non-zero
coefficient in all of the samples when using SSCE, while all other posterior inclusion proba-
bilities are similar between the two methods (see Table 4.4). The differences in adjustment
for the SAPSII score most likely explain why BSSL suggests a more favorable treatment
effect than SSCE. When using BSSCE, the SAPSII score has a non-zero coefficient in 66.2%
of posterior samples. The difference in inclusion probabilities between SSCE and BSSCE
suggests the SAPSII score is either only related to treatment, or a confounder strongly
related to treatment and weakly related to outcome that could decrease MSE when setting
its coefficient to zero according to the formula in Chapter 3.3.4.
3.6 Discussion
We have proposed two novel Bayesian methods for variable selection and estimation in
causal inference that simultaneously model the outcome and treatment assignment using
spike and slab priors on the model coefficients. By simultaneously modeling the outcome
and treatment assignment, the proposed methods can identify confounding variables with
weak associations in one model that may otherwise be ignored by a procedure using only
that model, such as the Bayesian lasso on the outcome model. Furthermore, both ap-
proaches show substantial improvements over BAC with ω =∞. SSCE aims to only adjust
for covariates related to outcome or treatment assignment in order to minimize bias. Addi-
tionally, our proposed method, SSCE, very infrequently includes irrelevant covariates that
are unrelated to outcome and treatment assignment, which can greatly reduce variability
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and the MSE of the treatment effect estimator in finite samples compared to competing
approaches such as BAC. On the other hand, BSSCE aims to reduce MSE of the treatment
effect estimator by setting coefficients to zero for those covariates which if included in the
outcome model would otherwise increase MSE of the treatment effect estimator. BSSCE
provides an effective means of reducing MSE without having to data-adaptively choose
a tuning parameter like ω in BAC. Furthermore, unlike BAC or other model averaging
techniques, the proposed approaches performed well even when the number of covariates
exceeded the sample size.
Another advantage of our approach is that it allows the variability of all parameters –
including both the treatment effect and covariate inclusion probabilities – to be summarized
from their posterior distributions. When using non-Bayesian methods such as the standard
lasso or simultaneous variable selection technique proposed in Chapter 2, the variance of
parameter estimators is often difficult to estimate; with many covariates or subjects, re-
sampling methods can be computationally intensive as parameters must be re-estimated
many times, and in some cases the bootstrap is not guaranteed to consistently estimate the
relevant limiting distributions (Chatterjee and Lahiri, 2011).
A linear model was assumed throughout the, but the proposed method could be extended
to more complicated models with covariate-covariate interactions, polynomial transforma-
tions of covariates, covariate-treatment interactions, or smoothers of various kinds (e.g.,
penalized splines expressed as mixed linear models). However, additional work needs to be
done for such extensions as the ideal grouping structure for interactions and transformations
is unclear.
3.7 Supplementary Materials
3.7.1 Supplement A: Gibbs sampler for SSCE and BSSCE
We now describe how to implement SSCE and BSSCE.
• First, set τ2 to a large constant to prevent coefficient shrinkage bias (τ2 is set to 1000 in
all simulations and the application in the main manuscript).
The following conditional distributions are then used in the Gibbs samplers for SSCE and
BSSCE (draw each parameter from its conditional distribution M times, where M is large):
•σ2|β, τ2 ∼ IG
(




j=1 I(βj 6= 0) + 0.1, scale =
1
2 (Y−Xoutβ)







where IG denotes the Inverse Gamma distribution,
•π0|β ∼ Beta(1 + p−
∑p
j=1 I(βj 6= 0), 1 +
∑p
j=1 I(βj 6= 0)).
• If Ai = 0 : A∗i |γ,Xi ∼ TN(Xiγ, 1)−,
• If Ai = 1 : A∗i |γ,Xi ∼ TN(Xiγ, 1)+,
where TN(Xiγ, 1)
− denotes the Truncated Normal distribution with support (−∞, 0) and
TN(Xiγ, 1)
+ denotes the Truncated Normal distribution with support (0,∞).
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• If using BSSCE:
• Calculate Qj = Varβ̂A(βj , γj ; X−j)−Varβ̂A(βj , γj ; X−j , Xj) + Biasβ̂A(βj , γj ; X−j , Xj)
2
for j = 1, . . . , p, where
































• For j = 1, . . . , p, if Qj < 0 then set βj and γj equal to zero.
3.7.2 Supplement B: A motivating example for SSCE
A simplified example is presented here to illustrate the properties and behavior of SSCE.





trtMtrt = nIn, and M
T
outiMoutj = 0, and M
T
trtiMtrtj = 0 for i 6= j, where Moutj
and Mtrtj denote the jth columns in Mout and Mtrt, respectively. Note that this means
there are no columns for intercepts in Mout and Mtrt and also no column for the treatment
effect in Mout (i.e., βA = 0). When BSSL is used on only Mout, the posterior probability
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that βj is zero is
P (βj = 0|Y,Mout) =
π0






where β̂lsj is the least squares estimator of βj under a full model. Equation (3.3) is plotted
in black in Figure 3.1 of the main manuscript (for fixed τ2j ); the colored lines in Figure
3.1 of the main manuscript show the posterior probability that βj is zero under SSCE (for
identical values of the π0, n, σ
2, and τ2j ), which is
P (βj = 0|O,Mout,Mtrt) =
π0













where γ̃j is the maximum likelihood estimator of γj under a full model.
The posterior distribution of βj for fixed τ
2
j under design matrices Mout and Mtrt is a
spike and slab distribution,
βj |O,Mout,Mtrt ∼ P (βj = 0|O,Mout,Mtrt)δ0(βj)








where P (βj = 0|O,Mout,Mtrt) is given in (3.4) and B = 11+nτ2j .
3.7.3 Supplement C: Covariate inclusion criteria for SSCE and BSSCE
Now we only assume that the design matrices for the outcome and treatment models, Xout
and Xtrt, have standardized covariates (as in Chapter 3.2.2 of the main manuscript). The
conditional probability that βj (and γj) is zero under SSCE is (with Z and O defined as in
Chapter 3.3.1 of the main manuscript)
P ((βj , γj)
T = 0|Z,O, A, σ2, π0, τ2j , β0, βA, β1, . . . , βj−1, βj+1, . . . , βp, γ0, γ1, . . . , γj−1, γj+1, . . . , γp) =
π0
π0 + (1− π0)στ−2j
(




















Y− β0 − βAA− p∑
k 6=j
βkXk
 and b = XTj




with Xj denoting the column in X for the jth covariate. Note that a and b are propor-
tional to the correlation between the jth covariate and the residual vectors without the jth
covariate in the outcome and treatment models, respectively.
Chapter 4





Randomized experiments are conducted every day to estimate the causal effect of a partic-
ular treatment or intervention on some outcome. There are currently a quarter of a mil-
lion interventional studies that are registered and have results posted on ClinicalTrials.gov.
Web-facing companies such as Amazon, Facebook, Google, and Netflix use online controlled
experiments to guide product development and accelerate innovation; at Microsoft’s Bing,
over 200 concurrent experiments are now running on any given day (Kohavi et al., 2013).
Results from a randomized experiment may sometimes suggest that a treatment or inter-
vention is particularly beneficial (or harmful) to some subgroup. When there are differential
effects of treatment, we say there is treatment effect heterogeneity.
Policy and medical decisions are often informed by the results of randomized studies, so
correctly characterizing treatment effect heterogeneity is important. For example, BiDil is
the first drug to be FDA-approved for a single racial group because study results suggest
it is beneficial for African-Americans with congestive heart failure. However, if BiDil is not
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truly beneficial for African-Americans with congestive heart failure (i.e., if a Type I error
was made), then production and marketing of the drug would prove to be very wasteful and
the potential side effects of BiDil would likely cause harm with no benefit for patients who
have received the drug.
Traditional approaches to characterizing treatment effect heterogeneity have centered
around regression modeling with interaction terms between the treatment/intervention in-
dicator and covariates. The magnitude and statistical significance of the interaction term
can be used to assess the degree of treatment effect heterogeneity. However, when there are
multiple interactions, regression models can quickly become difficult to interpret. Also, con-
clusions about the presence of interaction depend on the way in which interaction terms are
specified, so that important subgroups may not be identified. Lastly, considering multiple
interactions can inflate Type I error, but it is common not to adjust the significance level
for multiple testing, which leads to anti-conservative inference (Green and Kern, 2012).
Recently, there has been increasing interest in developing techniques to estimate het-
erogeneous treatment effects using more flexible models that can “automatically” detect
subgroups of interest. Athey and Imbens (2016) developed Causal Tree, which uses a sin-
gle regression tree to recursively partition the data into homogeneous subgroups that have
similar treatment effects and a similar subset of covariate values. Wager and Athey (2018)
extend Causal Tree to Causal Forests, which averages treatment effect estimates over many
Causal Trees. Green and Kern (2012) propose another method that uses multiple regres-
sion trees, called Bayesian Adaptive Regression Trees (BART), which automatically detects
nonlinear relationships and interactions to describe treatment effect heterogeneity. While
many of these approaches provide flexible subgroup identification, they typically do not
address the issue of inflation of Type I error.
In this chapter, we propose a novel method, called Treatment Effect Heterogeneity
Trees (TEHTrees), for characterizing treatment effect heterogeneity. TEHTrees combines
matching with conditional inference trees (Hothorn, Hornik, and Zeileis, 2006). One of its
main virtues is that, by employing formal hypothesis testing procedures in constructing the
tree, TEHTrees preserves the Type I error rate. In simulation studies comparing TEHTrees
and Causal Tree, the Type I error rate is below 0.05 in all considered scenarios using
TEHTrees, but is greater than 0.15 in all scenarios using Causal Tree (and far greater in
some cases). Though the power (defined as the probability of splitting on the variable
79
with true heterogeneous treatment effects) is slightly larger using Causal Tree compared to
TEHTrees in our simulations with continuous covariates, the power with binary covariates
is actually greater using TEHTrees compared to that of Causal Tree.
4.2 Method
4.2.1 Notation and Terminology
Let Y = {Y1, . . . , Yk, Yk+1, . . . , Yn} be the observed outcomes for k subjects randomized
to the control group and n − k subjects randomized to the treatment group. Throughout
we assume Y is a continuous outcome although the method could be generalized to binary
or categorical outcomes. An accompanying n ×m- dimensional matrix is denoted as X =
{X1, . . . , Xm}, where Xj denotes the jth predictor/covariate, and contains the m predictors
for each of the n subjects. The treatment assignment for all subjects is denoted as Z =
{Z1, . . . , Zn}.
4.2.2 Treatment Effects and Matching
Let Y1i be the potential outcome of subject i if assigned to treatment and Y0i be the potential
outcome of subject i if assigned to control. The measure of treatment effect heterogeneity
for a subject with covariates Xi is E(Y1i−Y0i|Xi). If we observed Y1i and Y0i for all i, then
to estimate E(Y1i−Y0i|Xi) we could simply construct a regression tree on the differences of
Y1i−Y0i to get an overall estimate of treatment effect heterogeneity within the population.
However, this is a counterfactual conditional statement because we do not observe both
Y1i and Y0i for any i. This is the fundamental difficulty with causal inference: for each
individual, we can only observe the outcome under treatment or the outcome under control
because each individual at a particular time will only receive the treatment or control.
One approach to estimating individual-level effects is via matching. In general, matching
is used to find a control subject j that is equivalent or similar across all covariates for each
treatment subject i. Assuming Xi = Xj , we can then use E(Yi−Yj |Xi) to estimate E(Y1i−
Y0i|Xi) for all i. That is, we can construct a regression tree (see next subchapter for more
on regression trees) on Yi − Yj , with Xi as the regression covariates in the tree, to estimate
E(Yi − Yj |Xi), which should approximate E(Y1i − Y0i|Xi). The resulting regression tree
partitions the covariate space into homogeneous subpopulations that have similar covariate
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values and estimates of E(Y1i−Y0i|Xi). The subpopulations formed from the regression tree
are defined hierarchically via a sequence of binary partitions of the covariate space. If the
predicted outcome for a subpopulation is much greater than that of another subpopulation,
then there is evidence that the treatment effect is heterogeneous in the study population
(i.e., the treatment is more beneficial or harmful to some subpopulation).
This approach requires implementation of an algorithm to match treated individuals
with controls. Stuart (2010) provides a comprehensive overview of past and current re-
search into matching methods and guidance on their use. She defines matching broadly as
“any method that aims to equate (or balance) the distribution of covariates in the treated
and control groups.” Several common methods include 1:1 matching, weighting, and sub-
classification. Theoretical basis for these procedures was developed in the 1970s beginning
with papers by Cochran and Rubin (1973) and Rubin (1973a) for situations with one covari-
ate. Matching on a single covariate is much simpler than matching on multiple covariates.
As the number of covariates increases, so does the difficulty in finding matches with close or
exact values of all covariates. Matching on the propensity score, defined as the probability
of receiving the treatment given the observed covariates, simplifies matching by not requir-
ing close or exact matches across all of the individual variables (Rosenbaum and Rubin,
1983; Stuart, Lee, and Leacy , 2013). It accomplishes this by collapsing the covariates into
a single measure, summarizing their joint association with treatment conditions (Hansen,
2008). Traditional propensity score methods are conducted without use of the outcome
variable, so the same propensity score procedure can be used for multiple outcomes. How-
ever, this prioritizes variables by their importance in predicting treatment assignment, not
outcome. Thus, variables that are strongly related to treatment assignment, but unrelated
to the outcome of interest may have excessive influence in the propensity score resulting in
decreased precision and increased bias in the treatment effect estimator (Stuart, Lee, and
Leacy , 2013).
A lesser known, but equally effective, measure that collapses an n×m matrix of covari-
ates into an n-dimensional vector is the prognostic score, formalized by Hansen (2008). We
call φ(X) a prognostic score if φ(X) is sufficient for Y0, in the sense that Y0 is independent
of X given φ(X). This may have several interpretations depending on the distribution of
the potential responses to control, Y0. Should Y0|X follow a generalized linear model, then
the linear predictor of Y0 given X is a prognostic score, as is the scalar E(Y0|X) (Hansen,
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2008). In this scenario, a prognostic score is estimated by fitting a model (we use the Super
Learner by van der Laan, Polley, and Hubbard (2007) in our simulations) of the outcome
in the control group and then using that model to obtain predictions of the outcome under
the control condition for all individuals (Stuart, Lee, and Leacy , 2013). The advantage to
using the prognostic score is that it reflects the relative importance of each covariate in pre-
dicting the outcome. However, diagnostics for prognostic balance are inherently incomplete
in that they address only balance among controls (Hansen, 2008). Fitting prognostic scores
using both treatment and control observations could also introduce bias if the pattern of
the treatment effect is not known a priori.
4.2.3 Conditional Inference Trees
As a solution to the downfalls of the standard approaches for developing clusters of indi-
viduals with shared characteristics, Morgan and Sonquist (1963) introduced a methodology
they called decision trees. Decision trees begin with one root node, containing the entire
sample, sometimes called the parent node. They then examine all possible independent
variables and select the one such that, if the sample is split according to that variable,
the resulting groups are most different with respect to the dependent variable according
to a predetermined criterion. The parent node then branches into two mutually-exclusive
child nodes according to the independent variable and split point that was selected. Within
each of the two child nodes, the tree-growing methodology repeats until a stopping rule
is satisfied. The final, mutually-exclusive and exhaustive subgroups of the population are
called terminal nodes. Since its development, the decision tree methodology has been ap-
plied in many areas of research including economics (Fan, Ong, and Koh, 2006), political
science (Feller and Holmes, 2009; Green and Kern, 2012), and life science (Gass et al., 2014;
Pouliakis et al., 2014; Faries et al., 2013).
Breiman et al. (1984) introduced a popular decision tree methodology called Classifica-
tion and Regression Tree (CART) analysis during the mid-1980s, which uses mean squared
error (MSE) of the outcomes as its splitting criterion. Despite its widespread popularity,
CART has several drawbacks, including a tendency to split the sample on variables that
have more potential splitting points (e.g. samples are more likely to be split on continuous
variables than binary when each has a similar association with the outcome). Also, CART
is predisposed to overfit the model because it is greedy when searching for optimal splits.
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Thus, it is often necessary to consider more or less aggressive stopping rules, or prune, in
order to obtain a tree that predicts well without overfitting in validation datasets.
One alternative decision tree method is the Conditional Inference Tree (CIT), proposed
by Hothorn, Hornik, and Zeileis (2006). CITs are different from CARTs in that the processes
of determining the variable to split on and determining the optimal split of the selected
variable occur sequentially instead of simultaneously. As our method relies on CITs, we
will provide a more in depth explanation of this algorithm in the following paragraphs.
For each parent node, the association on the p-value scale between the outcome and
each covariate is used to select the most optimal variable on which to split. P-values are
used in place of test statistics because the latter depend on the measurement scale and
number of possible splits of the covariates. The global null hypothesis of independence is
tested by considering all m partial null hypotheses of independence between the outcome
and each covariate. The global null hypothesis is rejected if the minimum computed p-value
for the m partial null hypotheses is less than a pre-specified level of significance. Multiple
comparison adjustment, such as the Bonferroni adjustment, is applied to the partial null
hypothesis tests. Finally, the partial null hypothesis that results in the smallest p-value will
indicate the covariate that is most strongly associated with the outcome. In the case where
no partial tests are rejected, the node is deemed to be a terminal node and no split is made.
After a covariate (say Xl) has been selected for splitting, the second step of the CIT
algorithm is to find the split point s that maximizes the discrepancy between the two
samples of outcomes that are obtained within the node based on if Xl < s. That is, if we
temporarily let A denote the set of indices that belong to the node under consider, for each
possible split point s, one can calculate a test statistic Ts that measures the discrepancy
between {Yi|Xli < s, i ∈ A} and {Yi|Xli ≥ s, i ∈ A}, and the desired split point maximizes
|Ts|. Some restrictions on the chosen split point (i.e., minimum or maximum values) may
be used to ensure the samples {Yi|Xli < s, i ∈ A} or {Yi|Xli < s, i ∈ A} do not have too
few observations.
This two-step process for determining splits provides both advantages and drawbacks
over the CART algorithm. Venkatasubramaniam et al. (2017) showed that CART may
provide slightly higher predictive accuracy and is less sensitive to sample size compared to
CIT. However, nodes formed through the CIT algorithm have a quantifiable relationship
between covariates and outcome amongst the individuals belonging to that node. Also,
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there is less worry about overfitting models using CIT so pruning is rarely necessary. Finally,
all covariates, assuming common association with the outcome, are similarly likely to be
selected as the splitting candidate no matter the number of potential split points.
4.2.4 TEHTrees
Characterizing treatment effect heterogeneity would be difficult using a CIT with the ob-
served outcomes (Y ) and covariates (X) because terminal nodes could contain no treated
(or untreated) subjects, which would complicate treatment effect estimation and obscure
intuition about which subgroups experience beneficial (or harmful) treatment effects. Addi-
tionally, since splits do not necessarily involve the treatment assignment, there would be a
greater chance that the tree would stop growing before important heterogeneous treatment
effects are discovered, especially when using a conservative method for multiple comparison
adjustment (like Bonferroni). The algorithm for characterizing treatment effect heterogene-
ity using a CIT is:
1. Split the sample in half.
Split the sample so that approximately half of the treated and half of the controls are
in one sample (call this the training sample), and the remaining subjects are in the
other sample (call this the estimation sample). The honest estimation technique of
Causal Tree also uses separate samples for tree-building and estimation.
2. Match each treated subject to a control subject (with replacement).
Form a set of matched pairs from the training the data, such that each pair contains
one treated and one control subject which are closely matched based on their prog-
nostic score. In particular, the Super Learner (van der Laan, Polley, and Hubbard,
2007) is used on the controls in the training sample only to model the outcome as
a function of the covariates (i.e., not including indicator for treatment assignment),
and this model is used to obtain the prognostic score (i.e., the estimated conditional
mean of the outcome given the observed covariates) for each individual in the training
sample. Each treated subject in the training sample is matched with the control that
has the prognostic score nearest (based on absolute distance) the prognostic score of
the treated subject; ties are broken randomly. Note that a control in the training
sample may be matched to multiple treated subjects, while it’s also possible that a
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control is not matched to any treated subject.
3. Calculate the within-pair differences in the outcome.
For each pair (there are as many pairs as treated subjects in the training sample),
calculate the within-pair difference in the outcome. We will use the within-pair dif-
ferences as outcomes in a CIT.
4. Build the tree.
Perform the partitioning within the CIT by repeating the following at each parent
node:
4a. Determine the splitting variable.
The p-values that determine whether to split the node (i.e., the p-values in the first
step of the iterative algorithm of the CIT described in Chapter 4.2.3) are derived us-
ing a linear mixed effects model. Since matching is performed with replacement (i.e.,
the same control subject could be matched to two or more different treated subjects),
the within-pair differences in outcomes are correlated even though the original ob-
servations are independent. This results in underestimated variances within a linear
regression model, and hence inflated Type I error from the standard CIT algorithm.
As an alternative, we use a linear mixed effects model to account for the correlated
outcomes. Particularly, the within-pairs difference in the outcomes are modeled as
the response in a linear mixed effects model with a random intercept denoting the
control that is used for each matched pair. Each model contains a single covariate as
a fixed effect. For each parent node, we fit a separate model for each covariate, so that
there are m total models (we fit models using the R package nlme). For each model,
a p-value is calculated using the Wald test corresponding the the null hypothesis that
the fixed effect is zero for the covariate in the model (a different model-based test
that measures the association between the within-pairs difference and each covariate
may also be used). If the smallest p-value (there are m total p-values) is greater than
or equal to αm , where α is the level of significance, then the node is a terminal node
(i.e., it is not split). Otherwise, the covariate corresponding to the smallest p-value is
chosen for splitting the node, and the split point of this covariate is described in the
next sub-step.
4b. Determine the split point.
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To determine the split point of a continuous covariate Xl, first consider a finite number
of split points, s1, . . . , sr (we consider equally spaced quantiles in our simulations).
The points s1 or sr can be restricted so that there are a minimum number of treated
and control observations in each of the child nodes in the estimation sample; note that
at least one treated and one control observation in the estimation sample are needed
in each terminal node for the estimation step below (we use a minimum of 10 treated
and 10 controls per node in the estimation sample). At the jth considered split point,
we use a linear mixed effects model with the same responses and random effect as the
previous sub-step, but with the covariate replaced with I(Xl < sj); the split point sj
that yields the largest absolute coefficient for I(Xl < sj) is chosen as the split point
for the node.
5. Estimate treatment effects.
Use the estimation sample to estimate the desired causal treatment effect in each ter-
minal node. We use the estimation technique of Causal Tree to estimate the treatment
effect in each node. The estimated treatment effect in a particular terminal node is
the mean of the outcomes of those treated in the estimation sample that belong to
the node (according to their covariate values) minus the mean of the outcomes of the
untreated subjects in the estimation sample that belong to the node. If the average
effect on the treated is desired, one can instead use as an estimate the mean of the
outcomes of the treated subjects in the estimation sample in each terminal node.
4.3 Simulation Study
We conducted simulations using R 3.2.2 (R Core Team, 2015) to test TEHTrees and com-
pare its performance to Causal Tree (Athey and Imbens, 2016), which extends the CART
algorithm to allow causal treatment effect estimation. Matching was conducted using the
Matching package (Sekhon , 2011), and all linear mixed models were fit using the nlme
package (Pinheiro et al., 2015). The Super Learner was used to estimate the prognostic
score and used the sample mean, a linear model (with and without interaction terms), a
generalized additive model, a Random Forest, stepwise regression (with and without inter-
action terms), and “polymars” (multivariate adaptive polynomial spline regression) as base
learners. The tree generating function TEHTrees had arguments specifying a minimum of
86
20 observations for a node to be considered for splitting and a p-value threshold of 0.05
for determining a candidate for splitting. Potential split points were tested at every 0.05
quantile of continuous candidate covariates.
4.3.1 Data Generation
The sample sizeN is varied in each scenario and the treatment variable Z was generated such
thatN/2 subjects received treatment (Z = 1) and theN/2 subjects received control (Z = 0).
Continuous covariates were generated from multivariate normal distributions with mean
zero, unit variance, and varying pairwise correlations. Binary covariates were generated as
independent Binomial(1, 0.5). Continuous outcomes were generated as independent N(µ, 1)
with linear predictor µ of the form:
g(µ) = α+ θZ + βX + γI(X1 > 0)Z.
We set α and θ to 0.8, β to (1.0, 0.8, 0.6, 0.4, 0.2)T for the first five covariates (0 oth-
erwise), and let γ equal either 0 (meaning there is no treatment effect heterogeneity) or 3
(meaning there is treatment effect heterogeneity). Results are based on 1,000 simulations
per scenario. The total number of covariates, type of covariates, and pairwise correlation
between covariates were varied in addition to the sample size.
4.3.2 Type I Error
In the context of this study, we define the Type I error to be any tree that results in
more than one terminal node when there is no treatment effect heterogeneity (i.e., when
γ = 0). Table 4.1 displays the Type I error of TEHTrees and Causal Tree under a variety
of scenarios. The Type I error of TEHTrees is less than the desired 0.05 level in all 23
scenarios. The Type I error of Causal Tree, on the other hand, is greater than 0.15 in
every scenario. As the sample size increases, the Type I error of Causal Tree increases and
even almost reaches 1.0 with 5 continuous covariates and N = 2000; the Type I error of
TEHTrees shows no pattern as the sample size increases.
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Table 4.1: Type I Error rate of TEHTrees and Causal Tree when there is no treatment
effect heterogeneity (i.e., when γ = 0). A Type I error occurs if the tree has more than
one terminal node (i.e., the tree splits on any variable). N is sample size, m is number of
covariates, and ρ is pairwise correlation.
Covariate Type N m ρ Type I Error Rate
TEHTrees Causal Tree
Binary 100 5 0.0 0.020 0.630
Binary 200 5 0.0 0.046 0.998
Binary 500 5 0.0 0.047 1.000
Binary 1000 5 0.0 0.041 1.000
Binary 2000 5 0.0 0.039 1.000
Continuous 100 5 0.0 0.025 0.303
Continuous 200 5 0.0 0.019 0.646
Continuous 500 5 0.0 0.025 0.936
Continuous 1000 5 0.0 0.027 0.991
Continuous 2000 5 0.0 0.026 1.000
Continuous 100 10 0.0 0.028 0.205
Continuous 200 10 0.0 0.016 0.416
Continuous 500 10 0.0 0.017 0.821
Continuous 1000 10 0.0 0.010 0.957
Continuous 2000 10 0.0 0.018 0.996
Continuous 200 5 0.2 0.030 0.687
Continuous 200 5 0.4 0.026 0.767
Continuous 200 5 0.6 0.026 0.825
Continuous 200 5 0.8 0.050 0.851
Continuous 500 5 0.2 0.023 0.970
Continuous 500 5 0.4 0.026 0.991
Continuous 500 5 0.6 0.030 0.994
Continuous 500 5 0.8 0.045 0.998
4.3.3 Power
The power is defined as the probability that the tree produces a split on X1 (the variable
with heterogeneity in treatment effects) when there is treatment effect heterogeneity (i.e.,
when γ = 3). Table 4.2 shows the power of TEHTrees and Causal Tree under the considered
scenarios. With binary covariates, TEHTrees displays greater power than Causal Tree for all
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Table 4.2: Power of TEHTrees and Causal Tree. Power is defined to be the probability
of the tree making a split on X1 when there is treatment effect heterogeneity (i.e., when
γ = 3). N is sample size, m is number of covariates, and ρ is pairwise correlation.
Covariate Type N m ρ Power
TEHTrees Causal Tree
Binary 100 5 0.0 0.62 0.48
Binary 200 5 0.0 1.00 0.69
Binary 500 5 0.0 1.00 0.84
Binary 1000 5 0.0 1.00 0.91
Binary 2000 5 0.0 1.00 0.94
Continuous 100 5 0.0 0.29 0.71
Continuous 200 5 0.0 0.63 0.94
Continuous 500 5 0.0 0.93 0.99
Continuous 1000 5 0.0 1.00 1.00
Continuous 2000 5 0.0 1.00 1.00
Continuous 100 10 0.0 0.18 0.54
Continuous 200 10 0.0 0.41 0.89
Continuous 500 10 0.0 0.81 1.00
Continuous 1000 10 0.0 0.96 1.00
Continuous 2000 10 0.0 1.00 1.00
Continuous 200 5 0.2 0.68 0.93
Continuous 200 5 0.4 0.72 0.89
Continuous 200 5 0.6 0.73 0.88
Continuous 200 5 0.8 0.66 0.83
Continuous 500 5 0.2 0.97 0.98
Continuous 500 5 0.4 0.98 0.98
Continuous 500 5 0.6 0.98 0.95
Continuous 500 5 0.8 0.95 0.94
sample sizes. With continuous covariates, the power is greater for Causal Tree with smaller
sample sizes compared to TEHTrees, but the power is similar between the two methods
with larger sample sizes.
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Table 4.3: Characteristics of the trees built by TEHTrees (TT) and Causal Tree (CT) when
there is treatment effect heterogeneity (i.e., when γ = 3), including the median and mean
of the first split point on X1 (the variable with heterogeneous treatment effects), along with
the proportion of those split points that are within the middle 5% of a standard normal
distribution (i.e., proportion in I = (−0.063, 0.063)), since the true split point is zero. The
average number of terminal nodes when a split is made is also shown. N is sample size, m
is number of covariates, and ρ is pairwise correlation.
Covariate N m ρ Median Mean Prop. # terminal
type split point split point splits in I nodes
TT CT TT CT TT CT TT CT
Binary 100 5 0.0 - - - - - - 2.00 1.75
Binary 200 5 0.0 - - - - - - 2.06 2.21
Binary 500 5 0.0 - - - - - - 2.11 2.56
Binary 1000 5 0.0 - - - - - - 2.11 2.99
Binary 2000 5 0.0 - - - - - - 2.11 3.37
Continuous 100 5 0.0 -0.01 -0.01 -0.01 -0.01 0.40 0.25 2.00 2.47
Continuous 200 5 0.0 0.00 0.00 0.00 0.00 0.53 0.39 2.10 3.90
Continuous 500 5 0.0 0.00 0.00 0.00 0.00 0.71 0.75 2.21 7.41
Continuous 1000 5 0.0 0.00 -0.00 0.00 -0.00 0.82 0.95 2.46 15.23
Continuous 2000 5 0.0 0.00 -0.00 0.00 -0.00 0.87 0.99 2.91 31.35
Continuous 100 10 0.0 -0.01 -0.03 -0.03 -0.02 0.40 0.24 2.00 2.29
Continuous 200 10 0.0 0.00 0.01 0.02 0.01 0.55 0.39 2.08 3.62
Continuous 500 10 0.0 0.00 0.00 0.00 0.00 0.73 0.64 2.16 4.39
Continuous 1000 10 0.0 0.00 0.00 0.00 0.00 0.82 0.86 2.34 4.56
Continuous 2000 10 0.0 0.00 0.00 0.00 -0.00 0.87 0.98 2.96 6.63
Continuous 200 5 0.2 0.00 0.00 0.00 0.00 0.51 0.40 2.13 4.43
Continuous 200 5 0.4 0.00 -0.00 0.00 -0.00 0.53 0.44 2.14 4.58
Continuous 200 5 0.6 0.00 0.00 -0.01 -0.00 0.49 0.43 2.16 4.76
Continuous 200 5 0.8 0.00 0.00 0.01 -0.01 0.52 0.44 2.16 4.54
Continuous 500 5 0.2 0.00 -0.00 0.00 -0.00 0.72 0.79 2.24 9.87
Continuous 500 5 0.4 0.00 -0.00 -0.01 -0.00 0.74 0.78 2.21 10.07
Continuous 500 5 0.6 -0.01 -0.00 0.00 -0.00 0.73 0.78 2.20 9.56
Continuous 500 5 0.8 -0.01 -0.00 -0.01 -0.01 0.73 0.75 2.24 9.10
4.3.4 Tree Characteristics Under Treatment Effect Heterogeneity
Table 4.3 provides characteristics of the trees built by TEHTrees and Causal Tree when
there is treatment effect heterogeneity (i.e., when γ = 3), including the median, mean, and
standard deviation of the set of points denoting the first split on X1 (the variable with
heterogeneous treatment effects), along with the proportion that are within the middle 5%
of a standard normal distribution (i.e., proportion in (−0.063, 0.063)) as the true split point
is zero. We can see from Table 4.3 that the mean and median split points are near zero for
both TEHTrees and Causal Tree, but the variability is greater for TEHTrees compared to
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Causal Tree. The proportion of split points in (−0.063, 0.063) is greater in smaller sample
sizes, but smaller in larger samples for TEHTrees compared to Causal Tree.
Table 4.3 also shows the average number of terminal nodes per tree in which a split
is made for TEHTrees and Causal Tree when there is treatment effect heterogeneity. The
average number of terminal nodes is near 2 when a split is made using TEHTrees, while
this number is much greater using Causal Tree; with N = 2000 independent continuous
covariates, there is an average of 31.35 terminal nodes using Causal Tree.
4.3.5 Treatment Effect Estimation
To evaluate the estimation properties of TEHTrees and Causal Tree when there was treat-
ment effect heterogeneity, we predicted the average treatment effect for all subjects i in the
estimation sample such that X1i > 0 (the subjects experiencing the most positive treatment
effect). The bias, standard deviation, and MSE of the treatment effect estimates are shown
in Table 4.4. With binary covariates, the magnitude of the bias and the MSE are much
smaller using TEHTrees compared to Causal Tree, and even with the largest considered
sample size (N = 2000), the MSE using TEHTrees is about 15 times smaller than that
of Causal Tree. With continuous covariates, the estimation performance is better using
Causal Tree compared to TEHTrees, but the differences in results between the methods
are smaller than with binary covariates; with five independent continuous covariates and
N = 2000 subjects, the MSE using Causal Tree is only about 1.5 times smaller than that
of TEHTrees.
4.4 Discussion
Randomized studies are often used to make medical decisions and inform policy. Sometimes
the results of randomized studies suggest that treatment effects are hetergeneous in a popu-
lation, which may be used to pursue interventions or market treatments that target specific
subgroups of the population. Recently, numerous methods have been proposed that aim to
discover treatment effect heterogeneity, including Causal Tree by Athey and Imbens (2016)
(which was later extended to Causal Forests by Wager and Athey (2018)). While many of
these approaches provide flexible subgroup identification, they typically do not address the
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Table 4.4: Bias, standard deviation (SD), and MSE of the estimated average treatment
effect for the subjects in the estimation sample that have X1 > 0 (i.e., the subjects in the
estimation sample with the greatest treatment effect) using TEHTrees (TT) and Causal
Tree (CT). N is sample size, m is number of covariates, and ρ is pairwise correlation.
Covariate N m ρ Bias SD MSE
type TT CT TT CT TT CT
Binary 100 5 0.0 -0.57 -0.81 0.88 0.87 1.09 1.40
Binary 200 5 0.0 0.02 -0.51 0.32 0.76 0.10 0.84
Binary 500 5 0.0 0.01 -0.27 0.20 0.60 0.04 0.43
Binary 1000 5 0.0 0.00 -0.15 0.15 0.45 0.02 0.23
Binary 2000 5 0.0 0.00 -0.09 0.10 0.37 0.01 0.15
Continuous 100 5 0.0 -1.15 -0.75 0.90 0.86 2.13 1.29
Continuous 200 5 0.0 -0.71 -0.35 0.80 0.57 1.14 0.45
Continuous 500 5 0.0 -0.20 -0.13 0.46 0.33 0.26 0.12
Continuous 1000 5 0.0 -0.09 -0.05 0.23 0.20 0.06 0.04
Continuous 2000 5 0.0 -0.08 -0.02 0.15 0.13 0.03 0.02
Continuous 100 10 0.0 -1.30 -0.93 0.83 0.88 2.37 1.64
Continuous 200 10 0.0 -1.01 -0.44 0.80 0.63 1.65 0.58
Continuous 500 10 0.0 -0.37 -0.13 0.64 0.32 0.54 0.12
Continuous 1000 10 0.0 -0.14 -0.07 0.36 0.21 0.15 0.05
Continuous 2000 10 0.0 -0.08 -0.04 0.17 0.15 0.03 0.02
Continuous 200 5 0.2 -0.65 -0.40 0.82 0.64 1.10 0.57
Continuous 200 5 0.4 -0.56 -0.42 0.81 0.68 0.96 0.63
Continuous 200 5 0.6 -0.57 -0.43 0.82 0.68 1.10 0.64
Continuous 200 5 0.8 -0.59 -0.46 0.80 0.73 0.99 0.74
Continuous 500 5 0.2 -0.14 -0.14 0.43 0.38 0.20 0.16
Continuous 500 5 0.4 -0.13 -0.13 0.40 0.41 0.18 0.18
Continuous 500 5 0.6 -0.13 -0.17 0.40 0.45 0.18 0.23
Continuous 500 5 0.8 -0.16 -0.18 0.44 0.44 0.22 0.23
issue of preserving Type I error rate. We propose TEHTrees, a new method for character-
izing treatment effect heterogeneity that preserves the Type I error rate. TEHTrees uses
decision trees to characterize treatment effect heterogeneity by utilizing matching within a
conditional inference tree algorithm.
In simulation experiments, the Type I error rate using TEHTrees was below 0.05 (the
pre-specified significance level) in all 23 considered scenarios, while the Type I error using
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Causal Tree was at least 0.15 in every scenario and even greater than 0.9 in many cases.
Though Causal Tree has slightly greater power when there are continuous covariates, com-
pared to TEHTrees, the power when using TEHTrees is actually greater than the power
when using Causal Tree with binary covariates. When there is treatment effect hetero-
geneity, Causal Tree also tends to grow larger trees with more terminal nodes compared to
TEHTrees, particularly with larger sample sizes. This makes it more difficult to infer the
characteristics of groups that truly respond more (or less) to treatment when using Causal
Tree compared to TEHTrees.
With binary covariates, treatment effect estimation was improved in our simulations
when using TEHTrees compared to Causal Tree. However, Causal Tree displayed slightly
better estimation properties than TEHTrees with continuous covariates, which was most
likely due to greater variability in split points with TEHTrees. We conjecture that the
variability in split points is larger with TEHTrees than with Causal Tree due to bias in
the matching estimator. Decreasing bias in the matching estimator, or using an alternative
approach to estimating the outcomes that are used as inputs in the conditional inference
tree of TEHTrees, may therefore improve estimation of treatment effects with TEHTrees
when there are continuous covariates.
TEHTrees is a flexible algorithm that allows for numerous modifications. A different
matching algorithm can be implemented, an alternative prognostic score model can be
fitted, other criterion can be used to find the splitting variable or its split point, and
another estimation technique could be contrived and executed. The Bonferroni correction
method that is used to find the splitting variable in TEHTrees (in Step 4a) is likely too
conservative to detect small treatment effects when there are a large number of covariates
in the study. Alternative multiple comparison adjustment methods should be explored in
the case when there are many covariates. Controlling the false discovery rate may also be a
desirable alternative to multiple comparison adjustment methods when there are numerous
covariates. TEHTrees also does not account for the variability in the matching estimator,
so an extra step may be needed to control for the inflation of Type I error that might occur
in situations when good matches are difficult to obtain.
Though many simulation scenarios were considered in this chapter, a larger variety
of scenarios need to be considered. The prognostic score model, for example, was quite
simple. Future research will increase the complexity of the prognostic score model and
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will also explore alternative effect sizes and treatment effect patterns (such as continuous
interactions with treatment). Additionally, though we assume treatment is randomized
(as in a clinical trial) throughout this chapter, TEHTrees could be extended for use with
observational data; however, additional assumptions and steps in the algorithm would be
required to achieve balance in the covariates, so this extension is left for future research.
Chapter 5
Conclusion and Discussion
Doubly robust estimation of the average causal treatment effect requires working models
for both the outcome and treatment given possible confounders. When the number of pos-
sible confounders is large it is natural to consider some form of variable selection for the
outcome and treatment models. GLiDeR, which is proposed in Chapter 2, uses an adaptive
group lasso approach to perform coefficient regularization and estimation across both treat-
ment and outcome models simultaneously, unlike traditional methods that consider only one
model and are thus more likely to exclude important confounders with weak associations in
the model under consideration. GLiDeR has desirable theoretical properties, and in simula-
tion experiments outperforms doubly robust approaches which do not incorporate variable
selection. It achieves similar efficiency with existing techniques which perform variable
selection across both outcome and treatment models, but has substantial computational
advantages over these approaches and allows for situations with p > n. Simulations suggest
the largest gains in efficiency are achieved when the outcome is misspecified, a frequent
occurrence in practice.
GLiDeR targets inference for the average causal treatment effect. Even though GLiDeR
displays good performance in the simulation scenarios considered in Chapter 2, we caution
that, like other model selection procedures, its finite sample performance at certain local
alternatives can potentially be quite poor, reminiscent of Hodges’ estimator (Leeb and
Pötscher, 2008). While the validity of bootstrap intervals was not explored in Chapter 2,
percentile bootstrap confidence intervals for the average causal effect had good coverage;
how to adapt promising recent developments in post-selection inference to our setting is an
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area of future research.
Alternatively, Chapter 3 proposes SSCE and BSSCE, two non-doubly robust Bayesian
approaches for variable selection and estimation in causal inference that allow the variabil-
ity of all parameters to be summarized from their posterior distributions. Both SSCE and
BSSCE use spike and slab priors on the model coefficients to simultaneously model the out-
come and treatment assignment. By simultaneously modeling the outcome and treatment
assignment, like GLiDeR, the SSCE and BSSCE can identify confounding variables with
weak associations in one model that may otherwise be ignored by a procedure using only
that model, such as the Bayesian lasso on the outcome model. Furthermore, both SSCE
and BSSCE show substantial improvements over BAC with ω = ∞. SSCE aims to only
adjust for covariates related to outcome or treatment assignment in order to minimize bias.
Additionally, SSCE very infrequently includes irrelevant covariates that are unrelated to
outcome and treatment assignment, which can greatly reduce variability and the MSE of
the treatment effect estimator in finite samples compared to competing approaches such as
BAC. On the other hand, BSSCE aims to reduce MSE of the treatment effect estimator
by setting coefficients to zero for those covariates which if included in the outcome model
would otherwise increase MSE of the treatment effect estimator. BSSCE provides an effec-
tive means of reducing MSE without having to data-adaptively choose a tuning parameter
like ω in BAC. Furthermore, unlike BAC or other model averaging techniques, the proposed
approaches performed well even when the number of covariates exceeded the sample size.
A linear model was assumed for the outcome throughout Chapters 2 and 3, but the
proposed methods in those chapters could be extended to more complicated models with
covariate-covariate interactions, polynomial transformations of covariates, covariate-treatment
interactions, or smoothers of various kinds (e.g., penalized splines expressed as mixed lin-
ear models). However, additional work needs to be done for such extensions as the ideal
grouping structure for interactions and transformations is unclear.
In Chapter 4, we move beyond average treatment effect estimation and propose TEHTrees,
a new method for estimating heterogeneous causal treatment effects. Randomized studies
are often used to make medical decisions and inform policy. Sometimes the results of ran-
domized studies suggest that treatment effects are heterogeneous in a population, which
may be used to pursue interventions or market treatments that target specific subgroups
of the population. Recently, numerous methods have been proposed that aim to discover
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treatment effect heterogeneity, including Causal Tree by Athey and Imbens (2016) (which
was later extended to Causal Forests by Wager and Athey (2017)). While many of these
approaches provide flexible subgroup identification, they typically do not address the issue
of preserving Type I error rate. We propose TEHTrees, a new method for characterizing
treatment effect heterogeneity that preserves the Type I error rate. TEHTrees uses de-
cision trees to characterize treatment effect heterogeneity by utilizing matching within a
conditional inference tree algorithm.
In simulation experiments, the Type I error rate using TEHTrees was below 0.05 (the
pre-specified significance level) in all 23 considered scenarios, while the Type I error using
Causal Tree was at least 0.15 in every scenario and even greater than 0.9 in many cases.
Though Causal Tree has slightly greater power when there are continuous covariates, com-
pared to TEHTrees, the power when using TEHTrees is actually greater than the power
when using Causal Tree with binary covariates. When there is treatment effect hetero-
geneity, Causal Tree also tends to grow larger trees with more terminal nodes compared to
TEHTrees, particularly with larger sample sizes. This makes it more difficult to infer the
characteristics of groups that truly respond more (or less) to treatment when using Causal
Tree compared to TEHTrees.
With binary covariates, treatment effect estimation was improved in our simulations
when using TEHTrees compared to Causal Tree. However, Causal Tree displayed slightly
better estimation properties than TEHTrees with continuous covariates, which was most
likely due to greater variability in split points with TEHTrees. We conjecture that the
variability in split points is larger with TEHTrees than with Causal Tree due to bias in
the matching estimator. Decreasing bias in the matching estimator, or using an alternative
approach to estimating the outcomes that are used as inputs in the conditional inference
tree of TEHTrees, may therefore improve estimation of treatment effects with TEHTrees
when there are continuous covariates.
TEHTrees is a flexible algorithm that allows for numerous modifications. A different
matching algorithm can be implemented, an alternative prognostic score model can be
fitted, other criterion can be used to find the splitting variable or its split point, and
another estimation technique could be contrived and executed. The Bonferroni correction
method that is used to find the splitting variable in TEHTrees (in Step 4a) is likely too
conservative to detect small treatment effects when there are a large number of covariates
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in the study. Alternative multiple comparison adjustment methods should be explored in
the case when there are many covariates. Controlling the false discovery rate may also be a
desirable alternative to multiple comparison adjustment methods when there are numerous
covariates. TEHTrees also does not account for the variability in the matching estimator,
so an extra step may be needed to control for the inflation of Type I error that could occur
in situations when good matches are difficult to obtain.
Though many simulation scenarios were considered in Chapter 4, a larger variety of
scenarios need to be considered. The prognostic score model, for example, was quite simple.
Future research will increase the complexity of the prognostic score model and will also
explore alternative effect sizes and treatment effect patterns (such as continuous interactions
with treatment). Additionally, though we assume treatment is randomized (as in a clinical
trial) throughout Chapter 4, TEHTrees could be extended for use with observational data;
however, additional assumptions and steps in the algorithm would be required to achieve
balance in the covariates, so this extension is left for future research.
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